Category: For physicians

  • Dr. Gurpreet Singh Padda beside the title card reading Your Anxiety Is a Fire in Your Gut, The Angry Gut, Chapter 1

    Inflammation and Depression: Identifying the Inflamed Subgroup

    Your Anxiety Is a Fire in Your Gut | The Angry Gut, Chapter 1

    Inflammation and Depression: Identifying the Inflamed Subgroup

    Inflammation is linked to depression in a subgroup, not in everyone: a meta-analysis of 30 studies found CRP above 3 mg/L in 27 percent of patients with depression. The treatment signal sits where baseline CRP is high, so identifying that subgroup starts with measurement.

    Anti-inflammatory trials in depression fail on average and succeed in the patients whose markers run high. That makes baseline measurement a clinical decision rather than an academic one.

    The link between inflammation and depression is real, and it is not universal. Treated as a population average it looks weak; treated as a subgroup question it becomes a screening problem primary care is well placed to solve. The case is set out in Your Anxiety Is a Fire in Your Gut, the video accompanying the first clinical chapter of The Angry Gut, which frames the gut as the first brain and the organ in the skull as the second.

    Measura [Cardiometabolic and Autonomic Health Analysis] supplies measurements to that workup. Diagnosis and management remain with the treating physician.

    Can inflammation cause depression?

    Endotoxin challenge in healthy volunteers produces depressed mood under randomized, placebo-controlled conditions, and in younger women the rise in interleukin-6 tracked the rise in depressed mood. The clinical analogue is interferon therapy for hepatitis C: across 26 prospective studies, the cumulative incidence of induced major depression was 0.25 at 24 weeks and 0.28 at 48. A prior depressive episode (OR 3.96) and higher baseline interleukin-6 predicted it.

    Susceptibility varies more than the cytokine response does. In one hundred and fifteen healthy adults challenged with endotoxin, baseline perceived stress, social sensitivity and existing anxiety or depressive symptoms predicted mood decline, yet none of them related to the magnitude of cytokine increases, and differential AP-1 and NF-kB activation was already visible at thirty minutes. The inflammatory stimulus is common. The vulnerability is individual, and it is partly social.

    How common is inflamed depression, and who responds to treatment?

    A meta-analysis of 30 studies found CRP above 3 mg/L in 27 percent of patients with depression, with an odds ratio of 1.46 against controls, and above 1 mg/L in 58 percent. The inflamed fraction was not explained by sample source, antidepressant treatment, age, BMI or ethnicity.

    Infliximab in treatment-resistant depression showed no overall effect but a significant interaction with baseline CRP. Above 5 mg/L, 8 of 13 patients responded against 3 of 9 on placebo, numbers too small to stand alone. Pooled across anti-inflammatory agents added to antidepressants, the effect reached SMD −0.64, from trials that all carried high risk of bias. The signal sits where the markers are high, which makes baseline measurement the decision point.

    The strongest counterargument

    Mendelian randomization in 68,769 Norwegian adults found no clear causal effect of genetically predicted CRP on depressive symptoms, and a UK Biobank analysis of the interleukin-6 receptor produced an odds ratio of 1.023. These designs estimate lifelong genetic set-points against questionnaire outcomes in general populations. They do not model inflammation acquired through adiposity, diet, barrier failure or repeated antibiotic courses, and none was conducted in metabolically ill, high-CRP patients. They argue against inflammation as the engine of depression population-wide, which is not the claim, and they are silent on the inflamed subgroup.

    Where the fire is lit: the first brain

    Gut-derived serotonin, roughly 90 to 95 percent of the body’s total, does not cross the blood-brain barrier. Dr. Padda describes having taught patients the opposite for years before the pharmacology corrected him. The routes that matter are vagal afferent signaling and cytokine induction of indoleamine 2,3-dioxygenase, which shunts tryptophan into the kynurenine pathway and leaves less for central synthesis.

    Barrier proxies point the same way. Serum IgM and IgA against gram-negative lipopolysaccharide separated patients with major depression from controls with an area under the ROC curve of 90.1 percent. In married couples, hostile interaction tracked lipopolysaccharide-binding protein, and 79 percent of the highest quartile had mean daytime CRP above 3, against 21 percent of the lowest. Stool microbiome signatures are not a usable screen: across 59 case-control studies the shifted taxa were shared between disorders. Measura does not perform stool, breath or microbiome testing.

    Inflammation and depression: who to measure and what a finding changes

    • Depression or anxiety with metabolic features such as central adiposity or elevated fasting insulin.
    • Treatment-resistant or partially responsive depression, particularly with coexisting bowel symptoms.
    • Repeated antibiotic exposure or heavy polypharmacy; in vitro, 24 percent of drugs with human targets inhibited at least one gut bacterial strain.
    • Positive depression screening at an annual wellness visit with no inflammatory or metabolic markers on file.

    A practical measurement set: laboratory panels with CRP and fasting insulin selected by the ordering physician, repeating any elevated CRP because infection, injury and strenuous exercise raise it; bioimpedance body composition to quantify the adipose compartment; and heart rate variability as a resting autonomic index. A confirmed elevated CRP with metabolic findings moves management toward the terrain the book calls metaflammation, running alongside existing psychiatric care. It is not a basis for altering an antidepressant, which remains with the prescriber.

    Pairing with cognition, and what intervention evidence supports

    In older adults, mood, inflammatory status and cognition are usually raised at the same visits. A structured cognitive assessment recorded alongside the inflammatory markers establishes a baseline for later comparison, in line with the cognitive assessment and fall prevention protocol.

    On the intervention side, dietary change carries the strongest data. SMILES randomized adults with major depression to dietary or social support and found a 7.1-point MADRS difference, an effect size of −1.16, remission of 32.3 against 8.0 percent and a number needed to treat of 4.1. Pooled dietary trials look smaller (g = 0.162), but 15 of 16 of them enrolled people without clinical depression. Probiotic effects shrink by nearly a third once high-bias trials are excluded.

    Workflow and documentation

    Specialty separation is the structural driver: mood, bowel and metabolism are managed in separate clinics, and nobody owns the connection. A standing order tying positive depression screening to CRP, fasting insulin and body composition turns the subgroup question into routine practice. Discrete results in the chart support HEDIS and value-based care documentation and annual wellness visit care plans, and let a repeat CRP be trended rather than rediscovered.

    Full effect sizes, confidence intervals, and the transplant and vagus stimulation trials are compiled in the Chapter 1 Deep Dive for The Angry Gut by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes. The preceding physician discussion covers autonomic function testing when symptoms begin in the gut. Depression that has lifted still leaves a cognitive risk worth tracking, addressed in remitted depression and cognitive decline.

    Frequently asked questions

    What proportion of patients with depression have elevated CRP?

    In a meta-analysis of 30 studies, 27 percent of patients with depression had CRP above 3 mg/L and 58 percent above 1 mg/L, with an odds ratio of 1.46 against controls at the higher cutoff. The inflamed fraction was not explained by antidepressant use, age, BMI or ethnicity. See clinical rationale.

    Should CRP be repeated before acting on it?

    Yes. CRP rises with infection, injury and strenuous exercise, and the 3 and 5 mg/L thresholds used in depression research are research cut-offs. A single elevated value warrants repetition and a search for a cause before it is documented as low-grade inflammation or used to redirect management. See interpreting the report.

    Do Mendelian randomization studies rule out inflammatory depression?

    They argue against inflammation as a major driver across general populations. They estimate lifelong genetic differences in CRP or interleukin-6 signaling against symptom questionnaires, and they were not conducted in metabolically ill, high-CRP patients. The inflamed-subgroup hypothesis remains untested by that design. See specialty applications.

    Is microbiome testing useful in a depression workup?

    Not currently. Case-control microbiome findings are shared across depression, bipolar disorder, schizophrenia and anxiety, and they shrink once medication, stool consistency and personality are accounted for. Measura does not perform stool or microbiome testing; blood markers and body composition are the measurable proxies for the inflamed terrain. See selection criteria.

    Does an elevated CRP change antidepressant management?

    Not by itself. Antidepressant decisions stay with the prescriber. A confirmed elevated CRP with metabolic findings adds a parallel line of management aimed at insulin resistance, adiposity and diet, and flags a patient in whom anti-inflammatory response data are strongest. Clear documentation lets the whole care team see it. See getting diagnostic results into the chart.

    How is inflammatory depression treated?

    Anti-inflammatory drugs added to antidepressants showed an effect in pooled trials, but every one of those trials carried a high risk of bias, and infliximab helped only where baseline CRP ran high. Dietary change carries the strongest data: in the SMILES trial, remission reached 32.3 percent against 8.0 percent. A confirmed high CRP with metabolic findings adds management aimed at insulin resistance, adiposity and diet, alongside existing psychiatric care.

    What are the signs that depression is linked to inflammation?

    No single symptom marks it. The profile worth measuring is depression or anxiety with metabolic features such as central adiposity or elevated fasting insulin, depression that is treatment-resistant or only partly responsive, especially with bowel symptoms, and repeated antibiotic courses or heavy polypharmacy. The measurable sign is a CRP above 3 mg/L, confirmed on a repeat draw, which a meta-analysis found in 27 percent of patients with depression.

    Does inflammation cause depression in everyone who has it?

    No. In healthy adults given endotoxin, perceived stress, social sensitivity and existing anxiety or depressive symptoms predicted who became depressed, yet none of them tracked the size of the cytokine rise. The inflammatory stimulus is common; the vulnerability is individual and partly social. That is why the link looks weak as a population average and strong in the inflamed subgroup.

    Bring inflammatory screening into your depression workflow

    See how the Measura protocol pairs laboratory panels, body composition and autonomic measures with standing orders for patients with depression and metabolic risk.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Udina, M., Castellví, P., Moreno-España, J., Navinés, R., Valdés, M., Forns, X., Langohr, K., Solà, R., Vieta, E., & Martín-Santos, R. (2012). Interferon-induced depression in chronic hepatitis C: A systematic review and meta-analysis. The Journal of Clinical Psychiatry, 73(8), 1128–1138. https://doi.org/10.4088/JCP.12r07694
    • Irwin, M. R., Cole, S., Olmstead, R., Breen, E. C., Cho, J. J., Moieni, M., & Eisenberger, N. I. (2019). Moderators for depressed mood and systemic and transcriptional inflammatory responses: A randomized controlled trial of endotoxin. Neuropsychopharmacology, 44(3), 635–641. https://doi.org/10.1038/s41386-018-0259-6
    • Osimo, E. F., Baxter, L. J., Lewis, G., Jones, P. B., & Khandaker, G. M. (2019). Prevalence of low-grade inflammation in depression: A systematic review and meta-analysis of CRP levels. Psychological Medicine, 49(12), 1958–1970. https://doi.org/10.1017/S0033291719001454
    • Raison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013). A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: The role of baseline inflammatory biomarkers. JAMA Psychiatry, 70(1), 31–41. https://doi.org/10.1001/2013.jamapsychiatry.4
    • Köhler-Forsberg, O., N Lydholm, C., Hjorthøj, C., Nordentoft, M., Mors, O., & Benros, M. E. (2019). Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: Meta-analysis of clinical trials. Acta Psychiatrica Scandinavica, 139(5), 404–419. https://doi.org/10.1111/acps.13016
    • Bekkevold, O.-J., Damås, J. K., Brumpton, B. M., & Åsvold, B. O. (2023). The causal role of C-reactive protein and interleukin-6 on anxiety and depression symptoms and life satisfaction: Mendelian randomisation analyses in the HUNT study. Psychological Medicine, 53(16), 7561–7568. https://doi.org/10.1017/S0033291723001290
    • Kelly, K. M., Smith, J. A., & Mezuk, B. (2021). Depression and interleukin-6 signaling: A Mendelian randomization study. Brain, Behavior, and Immunity, 95, 106–114. https://doi.org/10.1016/j.bbi.2021.02.019
    • Maes, M., Kubera, M., & Leunis, J.-C. (2008). The gut-brain barrier in major depression: Intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuro Endocrinology Letters, 29(1), 117–124. https://pubmed.ncbi.nlm.nih.gov/18283240/
    • Jacka, F. N., O’Neil, A., Opie, R., Itsiopoulos, C., Cotton, S., Mohebbi, M., Castle, D., Dash, S., Mihalopoulos, C., Chatterton, M. L., Brazionis, L., Dean, O. M., Hodge, A. M., & Berk, M. (2017). A randomised controlled trial of dietary improvement for adults with major depression (the ‘SMILES’ trial). BMC Medicine, 15(1), 23. https://doi.org/10.1186/s12916-017-0791-y
    • Maier, L., Pruteanu, M., Kuhn, M., Zeller, G., Telzerow, A., Anderson, E. E., Brochado, A. R., Fernandez, K. C., Dose, H., Mori, H., Patil, K. R., Bork, P., & Typas, A. (2018). Extensive impact of non-antibiotic drugs on human gut bacteria. Nature, 555(7698), 623–628. https://doi.org/10.1038/nature25979

    Related reading

  • Dr. Gurpreet Singh Padda beside the title card reading You Have the Stomach of a Hyena, The Angry Gut, Chapter 0

    Autonomic Function Testing When Symptoms Begin in the Gut

    You Have the Stomach of a Hyena | The Angry Gut, Chapter 0

    Autonomic Function Testing When Symptoms Begin in the Gut

    Autonomic function testing for gut symptoms means heart rate variability, cardiac autonomic reflex tests and sudomotor testing. An abnormal pattern moves the differential toward a systemic autonomic process; a normal pattern does not exclude enteric disease.

    Every autonomic test in routine use is taken at the heart or the skin. The complaint often starts in an organ with its own nervous system and a vagal cable built largely for reporting.

    Autonomic function testing earns its place in primary care when the ordering physician knows which part of the autonomic system a result actually describes. Patients with bloating, erratic bowels, lightheadedness and fatigue often carry a functional label and no measurement of regulation at all. The anatomy reviewed in You Have the Stomach of a Hyena, the opening video for The Angry Gut, explains why the test belongs in that workup and where its reach ends.

    Measura [Cardiometabolic and Autonomic Health Analysis] performs the measurements; interpretation and the plan stay with the treating physician. Dr. Padda notes he taught the body from the top down for years before the fiber anatomy changed how he sequences this workup.

    The first brain runs locally

    In the book’s vocabulary the enteric nervous system is the first brain and the skull holds the second. The label is evolutionary: gut-wall nervous systems occur in animals such as hydra that have no central nervous system. Standardized whole-mount counts put the human enteric population at 168 million neurons, comparable to spinal cord, spread across at least 26 definable neuron types. Bowel segments with every extrinsic nerve severed still propel their contents.

    The clinically relevant detail is where central control matters. It is essential in the esophagus and weighs more in the stomach and distal colon than in the small intestine. In isolated human colon the slow phasic rhythm is myogenic and survives conduction blockade, while blocking enteric transmission lengthened the interval between contractions from 124 to 278.1 seconds. A normal cardiac autonomic study says nothing about that local circuitry, and an abnormal one does not localize to it.

    What the vagus carries, measured rather than quoted

    The 75 to 90 percent afferent figure repeated in reviews leans partly on a rat study whose authors reported a higher efferent share than accepted estimates. No direct afferent-to-efferent count exists for a human vagus. Human morphometry is more useful: in the abdominal vagus, 94 percent of fibers are unmyelinated, against a myelinated share of 54 percent at the cervical level in the same individuals. That is the profile of fine sensory cable.

    Two findings bear directly on test interpretation. Right cervical vagus nerves averaged about one and a half times the effective surface of the left and carried twice as many tyrosine-hydroxylase-positive, catecholaminergic fibers. Fascicle architecture is also species-dependent: the mouse cervical vagus is a single fascicle, whereas the human carries 7 in the neck and 16 in the abdomen. Heart-derived vagal indices therefore sample a mixed cable, and rodent vagal physiology crosses into human interpretation only with care.

    Can any test record the gut’s signal to the brain?

    Luminal signals reach the brainstem quickly. In mice, neuropod cells synapse onto vagal afferents and transmit within 60 to 800 ms, although only 18.9 percent of CCK-producing enteroendocrine cells contacted a nerve fiber, and whole-nerve firing took on the order of a minute to peak. No bedside instrument records that traffic.

    What a practice can record is systemic autonomic regulation, the downstream metabolic terrain, and the medications that alter the upstream gate. Human gastric pH, 1.0 to 2.5 in all 66 ambulatory subjects of one capsule study, is a capsule or probe measurement performed elsewhere. Stool, breath and microbiome studies are likewise outside Measura’s scope and are not offered.

    Who needs autonomic function testing, and what does a finding change?

    Reasonable candidates, consistent with Measura selection criteria:

    • Chronic gastrointestinal symptoms that travel with orthostatic lightheadedness, abnormal sweating or unexplained fatigue.
    • Established metabolic disease in which autonomic involvement would change the follow-up plan.
    • Long-term acid suppression or heavy polypharmacy, where the medication list is already reshaping what the gut receives.
    • Older adults with gut complaints plus a fall history or a cognitive concern.

    The core tools are heart rate variability for resting autonomic balance, cardiac autonomic reflex tests for standardized responses to breathing and posture, and sudomotor testing for sweat-gland function in the small nerve fibers of the hands and feet. An abnormal pattern moves the differential from an isolated functional bowel diagnosis toward a systemic autonomic process and justifies trending over time. A normal pattern does not exclude enteric disease; gastroparesis and achalasia disable within the gut itself.

    Autonomic results carry the most weight next to laboratory panels and bioimpedance body composition, because the terrain the first brain reports on is metabolic. The chronic end state traced through the book is metaflammation, which is assessed in blood and tissue compartments rather than in a heartbeat.

    Pairing with cognition and fall prevention

    The second brain is downstream of the first, so a gut-and-autonomic workup in an older patient is incomplete without a cognitive baseline. A structured cognitive assessment recorded at the same encounter gives a reference point for later change, and orthostatic findings belong in the fall-risk plan rather than a separate note. Sequencing is covered in the cognitive assessment and fall prevention protocol.

    Workflow, medications and documentation

    Specialty separation is the social driver. Gastroenterology owns the bowel, cardiology owns the heart rate, and a patient with symptoms in both rarely has a single owner. A standing order that triggers autonomic testing when defined gut and orthostatic criteria coexist takes that gap out of individual memory. Results filed as discrete values support annual wellness visit care planning and MIPS quality reporting as documentation of a measured, followed finding rather than a symptom list.

    Medication reconciliation belongs in the same visit. In three population cohorts totaling 1,815 people, the 211 using a proton pump inhibitor had lower gut microbial diversity, an observational result open to confounding by indication; in a small randomized trial, acid suppression improved colonization by a swallowed organism. These drugs have real indications. The review question is whether the indication still holds, not reflexive discontinuation.

    Primary figures and their limits, including the unresolved afferent ratio, are compiled in the Chapter 0 Deep Dive for The Angry Gut by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes. The inflammatory consequences for mood are taken up in identifying inflammatory depression in practice.

    Frequently asked questions

    Does heart rate variability measure vagal tone in the gut?

    No. Heart rate variability indexes autonomic modulation of the sinus node, and the cervical vagus that contributes to it is a mixed nerve with a substantial catecholaminergic fiber population, especially on the right. It does not sample the abdominal vagus or enteric circuitry. Treat it as a systemic regulatory marker. See interpreting the report.

    Is the vagus nerve mostly afferent?

    By fiber type its abdominal portion looks sensory, but the familiar 75 to 90 percent figure is not a human count. Human morphometry shows 94 percent unmyelinated fibers in the abdominal vagus, while a rat study cited for the ratio reported more efferents than assumed. Avoid charting the ratio as established fact. See clinical rationale.

    Which patients with gut symptoms warrant autonomic testing?

    Patients whose gastrointestinal complaints travel with orthostatic symptoms, sweating abnormalities or unexplained fatigue; patients with metabolic disease where autonomic involvement would change follow-up; and older adults with falls or cognitive concerns. Testing is most informative when paired with metabolic laboratory work and body composition. See standing orders that make screening reproducible.

    Can Measura assess gastric acid or the microbiome?

    No. Gastric pH requires capsule or probe studies, and stool, breath and microbiome studies are separate services performed elsewhere. Measura covers autonomic, vascular, metabolic laboratory, body composition, balance and cognitive measurements, which describe the systemic terrain in the same patient and return to the ordering physician. See specialty applications.

    How should autonomic findings be documented?

    As discrete values with the testing context recorded, filed where the care team can trend them, and linked to the problem list rather than buried in a scanned report. Repeat intervals should follow the clinical question. That structure supports annual wellness visit care planning and quality documentation. See getting results into the record.

    What is done during autonomic testing?

    The core tools are heart rate variability, which records resting autonomic balance; cardiac autonomic reflex tests, which record standardized heart rate and blood pressure responses to breathing and posture; and sudomotor testing, which checks sweat-gland function in the small nerve fibers of the hands and feet. Measura performs the measurements and returns them to the ordering physician, who keeps interpretation and the plan.

    What does an abnormal autonomic test mean when symptoms start in the gut?

    An abnormal pattern moves the differential away from an isolated functional bowel diagnosis and toward a systemic autonomic process, and it justifies trending the values over time. A normal pattern does not exclude enteric disease, because conditions such as gastroparesis and achalasia disable the gut from within. Every routine autonomic test is taken at the heart or the skin, not in the gut wall.

    Who interprets autonomic testing results?

    The treating physician. Measura performs the measurements; interpretation and the plan stay with the physician who ordered them. Results are most useful filed as discrete values next to laboratory panels and body composition, because the terrain the gut reports on is metabolic. A standing order that triggers testing when defined gut and orthostatic criteria coexist keeps the workup from depending on memory.

    See how autonomic testing fits your practice

    Review how the Measura protocol pairs autonomic, metabolic and cognitive measurements with standing orders and documentation inside an existing workflow.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Furness, J. B., & Stebbing, M. J. (2017). The first brain: Species comparisons and evolutionary implications for the enteric and central nervous systems. Neurogastroenterology and Motility, 30(2), e13234. https://doi.org/10.1111/nmo.13234
    • Michel, K., Kuch, B., Dengler, S., Demir, I. E., Zeller, F., & Schemann, M. (2022). How big is the little brain in the gut? Neuronal numbers in the enteric nervous system of mice, Guinea pig, and human. Neurogastroenterology and Motility, 34(12), e14440. https://doi.org/10.1111/nmo.14440
    • Furness, J. B., Marklund, U., Czapla, B. J., Bornstein, J. C., & Han, M. N. (2026). Functional characterization and classification of enteric neurons, and regional differences in neural control of digestive functions. Autonomic Neuroscience: Basic & Clinical, 265, 103412. https://doi.org/10.1016/j.autneu.2026.103412
    • Carbone, S. E., Dinning, P. G., Costa, M., Spencer, N. J., Brookes, S. J. H., & Wattchow, D. A. (2013). Ascending excitatory neural pathways modulate slow phasic myogenic contractions in the isolated human colon. Neurogastroenterology and Motility, 25(8), 670–676. https://doi.org/10.1111/nmo.12129
    • Prechtl, J. C., & Powley, T. L. (1990). The fiber composition of the abdominal vagus of the rat. Anatomy and Embryology, 181(2), 101–115. https://doi.org/10.1007/BF00198950
    • Stakenborg, N., Gomez-Pinilla, P. J., Verlinden, T. J. M., Wolthuis, A. M., D’Hoore, A., Farré, R., Herijgers, P., Matteoli, G., & Boeckxstaens, G. E. (2020). Comparison between the cervical and abdominal vagus nerves in mice, pigs, and humans. Neurogastroenterology and Motility, 32(9), e13889. https://doi.org/10.1111/nmo.13889
    • Verlinden, T. J. M., Rijkers, K., Hoogland, G., & Herrler, A. (2016). Morphology of the human cervical vagus nerve: implications for vagus nerve stimulation treatment. Acta Neurologica Scandinavica, 133(3), 173-182. https://doi.org/10.1111/ane.12462
    • Kaelberer, M. M., Buchanan, K. L., Klein, M. E., Barth, B. B., Montoya, M. M., Shen, X., & Bohórquez, D. V. (2018). A gut-brain neural circuit for nutrient sensory transduction. Science, 361(6408), eaat5236. https://doi.org/10.1126/science.aat5236
    • Imhann, F., Bonder, M. J., Vich Vila, A., Fu, J., Mujagic, Z., Vork, L., Tigchelaar, E. F., Jankipersadsing, S. A., Cenit, M. C., Harmsen, H. J. M., Dijkstra, G., Franke, L., Xavier, R. J., Jonkers, D., Wijmenga, C., Weersma, R. K., & Zhernakova, A. (2016). Proton pump inhibitors affect the gut microbiome. Gut, 65(5), 740-748. https://doi.org/10.1136/gutjnl-2015-310376
    • Singh, G., Haileselassie, Y., Briscoe, L., Bai, L., Patel, A., Sanjines, E., Hendler, S., Singh, P. K., Garud, N. R., Limketkai, B. N., & Habtezion, A. (2022). The effect of gastric acid suppression on probiotic colonization in a double blinded randomized clinical trial. Clinical Nutrition ESPEN, 47, 70-77. https://doi.org/10.1016/j.clnesp.2021.11.005

    Related reading

  • Dr. Gurpreet Singh Padda presenting the title card Empowered Individuals Change Their Communities, The Pained Brain, Chapter 22

    The Diabetes Prevention Program in Pain and Primary Care

    Empowered Individuals Change Their Communities | The Pained Brain, Chapter 22

    The Diabetes Prevention Program in Pain and Primary Care

    The Diabetes Prevention Program is a coached lifestyle intervention targeting 7 percent weight loss and 150 minutes of weekly activity. A referral from a pain or primary care practice should carry a documented baseline (A1c, fasting glucose, fasting insulin, kidney function and body composition) and an early recheck, because participants who see a result stay.

    Lifestyle intervention cut diabetes incidence by more than half in the trial that defined it. At national scale it reaches a sliver of eligible adults and delivers least to those at highest risk.

    The Diabetes Prevention Program is the strongest randomized evidence in American medicine that a coached lifestyle intervention changes metabolic outcomes, and it is also the clearest demonstration that proof is not delivery. For primary care, pain, endocrine and geriatric practices the practical question is not whether to refer. It is what should travel with the referral, and what measurement keeps the effect from leaking away between enrollment and week 52. The chapter video, Empowered Individuals Change Their Communities, presents the final chapter of The Pained Brain by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Dr. KrisJay Fucanan, MD; source-level grading is in the book companion for chapter 22.

    How well does the Diabetes Prevention Program work?

    The original trial randomized 3,234 adults with impaired glucose tolerance to placebo, metformin or a lifestyle program targeting 7 percent weight loss and 150 minutes of weekly activity. Over an average of 2.8 years, lifestyle reduced diabetes incidence by 58 percent and metformin by 31 percent, with 6.9 people needing the lifestyle program over three years to prevent one case. At 15 years the lifestyle hazard ratio was still 0.73, though cumulative incidence had reached 55 percent against 62 percent on placebo, and at 21 years the cumulative reduction stood at 24 percent.

    The ceiling came from established diabetes. Look AHEAD randomized 5,145 adults with type 2 diabetes to intensive lifestyle intervention; weight fell 8.6 percent at one year, and the cardiovascular composite did not differ, a hazard ratio of 0.95. What it did deliver was remission in 11.5 percent at one year against 2.0 percent with education.

    Where national scale loses the effect

    Scaled nationally, the program enrolled 455,954 people in eight years, set against an at-risk adult population of more than 88 million. Among the first 14,747 participants, median attendance was 14 sessions, 35.5 percent reached the 5 percent weight-loss goal, and each additional session was worth 0.3 percent of body weight. In-person delivery produced 4.4 percent average weight loss against 2.6 percent online, and participants who stayed for 22 sessions exceeded the 5 percent goal in every format.

    The losses concentrate where risk is highest. In-person weight loss ran 5.1 percent in non-Hispanic White participants against 3.3 percent in non-Hispanic Black and American Indian or Alaska Native participants, and 3.3 percent at ages 18 to 34 against 5.1 percent at 65 and older. Early success predicted staying: 41.0 percent of those who had lost nothing were retained, against 73.9 percent of those who had lost at least half a percent. Medicare has covered the program since 2018; in six years 9,015 beneficiaries participated, against roughly 5.2 million eligible, with about 1.5 delivery sites per 100,000 beneficiaries.

    What should a Diabetes Prevention Program referral include?

    The retention data argue for a documented baseline and an early recheck, because participants who see a result stay. That baseline should include more than glucose.

    • A1c and fasting glucose, with remission and progression defined in advance.
    • Fasting insulin or a HOMA-IR estimate, because insulin resistance can move substantially while glucose moves little; one company-funded remote-care cohort reported a 55 percent fall in HOMA-IR at one year.
    • Kidney function. In 1,779 Diabetes Prevention Program participants reassessed about 21 years after randomization, painful neuropathic symptoms tracked weight and lower eGFR and were not associated with glycemia.
    • Body composition, particularly when BMI is under 27. In 20 people with type 2 diabetes at that BMI, a 6.5 percent weight loss produced remission in 70 percent, and roughly one in six patients is diagnosed at that weight.
    • A weight target expressed as a percentage, with the musculoskeletal threshold noted for pain patients: knee osteoarthritis relief was anticipated at about 7 percent loss.

    For pain practices the musculoskeletal evidence is real and modest. Weight-loss interventions improved osteoarthritis pain by a standardized 0.54 against minimal care but were not better than exercise alone in knee osteoarthritis; pair the referral with dosed movement. Effects on pain beyond the joints are inferred from mechanism.

    Who should be referred to a Diabetes Prevention Program?

    • Adults with prediabetic glycemia, including those previously told their A1c was nothing to worry about.
    • Chronic pain patients with a metabolic phenotype: elevated glucose or A1c, a high triglyceride-to-HDL ratio, central adiposity.
    • Patients with type 2 diabetes and a normal BMI, in whom body composition changes the conversation.
    • Patients with painful neuropathic symptoms, where weight and kidney function deserve measurement alongside glycemia.
    • Household members of enrolled patients, since untreated spouses in lifestyle trials lost weight alongside the enrolled partner.

    Practice criteria are summarized under selection criteria.

    Measurement as the retention tool

    Education has a dose and a half-life. Diabetes self-management education lowered A1c by 0.57 on average with ten or more contact hours as the threshold, and pooled trajectories after face-to-face education showed an early reduction of about 1.3 percent drifting back toward baseline by 52 weeks, independent of program intensity. Feedback holds part of the gain: continuous glucose monitoring added 0.29 over fingersticks, and among 9,768 smart-scale users a gap of 30 days without weighing was associated with 1.37 kilograms of gain in those with obesity.

    Measura [Cardiometabolic and Autonomic Health Analysis] supplies the office-based side of that feedback loop. It is a testing service that reports to the ordering physician and does not treat or diagnose disease on its own. Laboratory panels provide the glycemic, lipid and renal markers, and bioimpedance body composition separates fat and lean mass so that a participant losing muscle is not recorded as a success. Repeat measurement at defined intervals turns a referral into a tracked episode rather than a handoff; the case for standing orders applies directly.

    The consultation is part of the dose

    How the referral is delivered changes what it does. In a 1987 trial of 200 general practice patients without a definite diagnosis, 64 percent were better at two weeks after a positive consultation against 39 percent after a negative one, while treatment itself made little difference. In 406 patients with newly chronic back pain, each point of perceived risk that the pain would persist slowed recovery at a hazard ratio of 0.91. Among 720 medical inpatients, hopelessness about one’s condition carried an adjusted odds ratio of 5.69 for a positive suicide screen, against 2.29 for chronic pain. Only 15.7 percent of primary care visits included counseling on diet, activity or stress.

    Standing orders and documentation

    A reproducible workflow is a standing order that attaches A1c, fasting glucose and insulin, a lipid panel, kidney function and body composition to every prevention-program referral, with a scheduled repeat early, when retention is decided, and again before the first year ends, when education effects fade. At an annual wellness visit, the same data support the cardiometabolic documentation tracked under HEDIS and value-based care, as quality documentation rather than an indication in itself. Filing results as structured fields through getting results into the record keeps the trend visible to every clinician in the chain. The mood and metabolic screening that precedes many of these referrals is in depression and insulin resistance screening; patients can read the patient version.

    Frequently asked questions

    What is a diabetes prevention program?

    A coached lifestyle program that targets 7 percent weight loss and 150 minutes of activity a week. In the original trial of 3,234 adults with impaired glucose tolerance, it cut new cases of diabetes by 58 percent over about 2.8 years. The national version has enrolled 455,954 people, and Medicare has covered it since 2018. A referral holds best with a documented baseline and an early recheck.

    What did the Diabetes Prevention Program trial show?

    In 3,234 adults with impaired glucose tolerance, an intensive lifestyle program cut diabetes incidence by 58 percent and metformin by 31 percent over about 2.8 years, with 6.9 people treated with lifestyle over three years to prevent one case. The benefit narrowed but persisted at 15 and 21 years. The wider basis for measurement is summarized in the clinical rationale.

    Why does national enrollment deliver less than the trial?

    Reach and retention. The national program enrolled 455,954 people against more than 88 million at risk, average weight loss fell short of 5 percent in every delivery mode, and younger, Black and American Indian participants lost less and left earlier. Participants who stayed 22 sessions exceeded the goal. Outcome implications are discussed in what changes for the patient.

    Which baseline measurements should accompany a referral?

    A1c and fasting glucose, fasting insulin, a lipid panel, kidney function and body composition, plus a weight target written as a percentage. Kidney function earns its place because painful neuropathic symptoms tracked weight and eGFR rather than glycemia over 21 years of follow-up, and body composition matters in patients with a BMI under 27. Panel options are under laboratory panels.

    Is weight loss relevant to chronic pain outcomes?

    In osteoarthritis, yes, at a modest size: a standardized 0.54 improvement in pain against minimal care, no better than exercise alone in the knee, and relief anticipated at about 7 percent weight loss. For spinal pain the evidence was limited and inconclusive, so broader pain effects should be documented as inferred from mechanism. Use by specialty is covered under specialty applications.

    How often should metabolic measures be repeated after referral?

    The retention and education data point to two moments that matter: early in the program, because participants who show initial loss are far more likely to stay, and before the one-year mark, because education effects on A1c attenuate toward baseline by 52 weeks. The exact interval is a clinical decision. Between-visit approaches are in chronic care and between-visit monitoring.

    Give the prevention referral a baseline and a recheck

    Learn how the Measura protocol attaches laboratory panels and body composition to lifestyle-program referrals, with repeat results returned to the ordering physician.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Knowler, W. C., Barrett-Connor, E., Fowler, S. E., Hamman, R. F., Lachin, J. M., Walker, E. A., Nathan, D. M., & Diabetes Prevention Program Research Group (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England Journal of Medicine, 346(6), 393–403. https://doi.org/10.1056/NEJMoa012512
    • Diabetes Prevention Program Research Group (2015). Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. The Lancet Diabetes & Endocrinology, 3(11), 866–75. https://doi.org/10.1016/S2213-8587(15)00291-0
    • Crandall, J. P., Dabelea, D., Knowler, W. C., Nathan, D. M., Temprosa, M., & Diabetes Prevention Program Research Group (2025). The Diabetes Prevention Program and Its Outcomes Study: NIDDK’s Journey Into the Prevention of Type 2 Diabetes and Its Public Health Impact. Diabetes Care, 48(7), 1101–1111. https://doi.org/10.2337/dc25-0014
    • Cannon, M. J., Ng, B. P., Lloyd, K., Reynolds, J., & Ely, E. K. (2022). Delivering the National Diabetes Prevention Program: Assessment of Enrollment in In-Person and Virtual Organizations. J Diabetes Res, 2022, 2942918. https://doi.org/10.1155/2022/2942918
    • Ely, E. K., Gruss, S. M., Luman, E. T., Gregg, E. W., Ali, M. K., Nhim, K., Rolka, D. B., & Albright, A. L. (2017). A National Effort to Prevent Type 2 Diabetes: Participant-Level Evaluation of CDC’s National Diabetes Prevention Program. Diabetes Care, 40(10), 1331–1341. https://doi.org/10.2337/dc16-2099
    • Ng, B. P., Ely, E., Papali’i, M., & Cannon, M. J. (2024). Delivering the National Diabetes Prevention Program: Assessment of Retention, Physical Activity, and Weight Loss Outcomes by Participant Characteristics and Delivery Modes. J Diabetes Res, 2024, 8461704. https://doi.org/10.1155/2024/8461704
    • Look AHEAD Research Group, Wing, R. R., Bolin, P., Brancati, F. L., Bray, G. A., Clark, J. M., Coday, M., Crow, R. S., Curtis, J. M., Egan, C. M., Espeland, M. A., Evans, M., Foreyt, J. P., Ghazarian, S., Gregg, E. W., Harrison, B., Hazuda, H. P., Hill, J. O., Horton, E. S., … Yanovski, S. Z. (2013). Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med, 369(2), 145–54. https://doi.org/10.1056/NEJMoa1212914
    • Herman, W. H., Ciarleglio, A., Callaghan, B. C., Edelstein, S. L., Goldberg, R., White, N. H., & Albers, J. W. (2025). Nonglycemic and Glycemic Risk Factors for Painful Neuropathic Symptoms and for Distal Symmetrical Polyneuropathy (DSPN) in the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. Diabetes Care, 48(10), 1676–1684. https://doi.org/10.2337/dc25-0596
    • Taylor, R., Barnes, A. C., Hollingsworth, K. G., Irvine, K. M., Solovyova, A. S., Clark, L., Kelly, T., Martin-Ruiz, C., Romeres, D., Koulman, A., Meek, C. M., Jenkins, B., Cobelli, C., & Holman, R. R. (2023). Aetiology of Type 2 diabetes in people with a ‘normal’ body mass index: testing the personal fat threshold hypothesis. Clinical Science, 137(16), 1333–1346. https://doi.org/10.1042/CS20230586
    • Dughmosh, R., Hamdan, A., Moghassabi, W., Al-Kahlout, L., Syed, A., Alwisi, N., Al-Sharif, N., Othman, M., & Doi, S. A. R. (2026). Glycemic trajectory after face-to-face diabetes self-management education: a dose-response meta-analysis. Diabetes Research and Clinical Practice, 238, 113375. https://doi.org/10.1016/j.diabres.2026.113375

    Related reading

  • Dr. Gurpreet Singh Padda presenting the title card You Cannot Separate the Mind from the Metabolism, The Pained Brain, Chapter 21

    Depression and Insulin Resistance: Screening the Pain Patient

    You Cannot Separate the Mind from the Metabolism | The Pained Brain, Chapter 21

    Depression and Insulin Resistance: Screening the Pain Patient

    Screen a pain patient with depression for insulin resistance: fasting glucose, A1c, the triglyceride-to-HDL ratio and body composition belong beside the PHQ-9. The two conditions predict each other, and the metabolic pattern predicts how far chronic pain spreads and how procedures perform.

    A positive depression screen in a pain patient usually produces a behavioral health referral. The metabolic data that predict how that patient’s mood, pain and procedures will behave rarely travel with it.

    Depression and insulin resistance tend to be charted by different clinicians, yet in patients with chronic pain the two predict each other, predict how far the pain spreads, and predict how an injection or an operation performs. A positive PHQ-9 in a pain or primary care clinic generates a referral; the fasting glucose, A1c, lipid ratio and body composition that belong beside it usually do not. The video You Cannot Separate the Mind from the Metabolism covers chapter 21 of The Pained Brain by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Dr. KrisJay Fucanan, MD. Evidence grading sits in the book companion for chapter 21; the concern here is what a primary care, pain, endocrine or geriatric practice should measure once mood and pain arrive together.

    How common is depression in chronic pain patients?

    In a synthesis of 376 studies and 347,468 people with chronic pain, clinically significant depressive symptoms ran 39.3 percent and diagnosed major depressive disorder 36.7 percent, with fibromyalgia at 54.0 percent. Heterogeneity approached 99 percent and screens were pooled with formal diagnoses, so the diagnosed figure is the conservative one. Pain also impairs the recognition and treatment of depression, so a busy procedural or primary care schedule underdetects it by default.

    A depression screen that ends the workup tells the patient her pain is psychological. A screen that extends the workup into the metabolic terrain does the reverse.

    Does insulin resistance predict depression, or the reverse?

    Cross-sectionally the association is modest, a pooled standardized effect of 0.19 in data excluding prevalent diabetes. Prospectively it is more informative. Baseline depression predicted incident type 2 diabetes at a relative risk of 1.60, and baseline diabetes predicted incident depression at 1.15. In the NESDA cohort, 601 adults without lifetime depression or anxiety were followed nine years: a higher triglyceride-to-HDL ratio predicted first-onset major depression at a hazard ratio of 1.89, fasting glucose at 1.37, waist circumference at 1.11, and prediabetes developing within two years at 2.66. These are surrogate measures rather than clamp studies, and new-onset lipid ratio elevation was not associated, but the metabolic signal preceded the mood disorder.

    The inflammatory subgroup is real and bounded. Across 37 studies, CRP exceeded 3 mg/L in 27 percent of depressed patients and 1 mg/L in 58 percent, at odds of 1.46 and 1.47 against matched controls, without variation by antidepressant treatment, age or BMI. Roughly three quarters fall below the higher threshold. CRP stratifies; it does not diagnose.

    Pharmacotherapy sits inside the same loop. In 294,719 adults in the UK Clinical Practice Research Datalink, antidepressant use carried an adjusted rate ratio of 1.21 for at least 5 percent weight gain, persisting at least six years, with one additional weight-gain episode per 27 patients treated in year two. Neither finding argues against prescribing. Both argue for a documented baseline weight, body composition and fasting glucose before the first dose.

    How does metabolic status change pain and procedure outcomes?

    In MIDUS, 24.2 percent of 781 adults showed a metabolic dysregulation phenotype defined by fasting glucose, HbA1c, HOMA-IR, triglycerides, waist-hip ratio and low HDL. About seven years later that phenotype carried a relative risk ratio of 2.00 for high-interference chronic pain and 2.03 for pain at three or more sites, while it did not predict the presence of chronic pain, an odds ratio of 1.18. The metabolic terrain forecasts spread and interference, which are the outcomes pain practices are asked to change.

    It also forecasts procedural yield. Across 346 patients in seven hospitals receiving epidural steroid injections, sacroiliac injections or facet radiofrequency ablation, depressive symptoms lowered the odds of success by an adjusted 0.94 per unit of score, obesity reduced relief, and poor baseline function cut the odds to 0.59. With metabolic syndrome, spine surgery carried 1.6 times the wound complications and 4.48 times the renal complications. Across 44 studies and 21,452 spine surgery patients, depressed patients started 0.52 standardized units worse and finished 0.52 worse, with identical improvement: the operation worked and the depression stayed.

    A documented mood and metabolic phenotype sets expectations before a procedure. It justifies treating layers together; in SCAMP, 250 primary care patients with musculoskeletal pain and a PHQ-9 of at least 10 who received optimized antidepressant therapy plus pain self-management reached combined improvement in depression and pain at 26.0 percent against 7.9 percent, a relative risk of 3.3. And it names the social driver neither specialty owns: in older Chinese adults without chronic pain at baseline, loneliness carried an odds ratio of 1.61 for incident chronic pain over seven years.

    Which pain patients should be screened for insulin resistance?

    • Chronic pain patients with a positive PHQ-9 or a documented depressive disorder.
    • Pain that is spreading to new sites or increasingly interfering with function.
    • Patients about to start or escalate an antidepressant associated with weight gain.
    • Candidates for epidural, sacroiliac, radiofrequency or spinal surgical procedures who have depressive symptoms, obesity or poor baseline function.
    • Patients with prediabetic glycemia or an elevated triglyceride-to-HDL ratio who have never been screened for mood.

    Selection thresholds for a practice are listed in selection criteria.

    What Measura measures in this pathway

    Measura [Cardiometabolic and Autonomic Health Analysis] is a testing service: it measures, returns results to the ordering physician, and does not diagnose depression or treat. Laboratory panels are the route for the glycemic, lipid and inflammatory markers used in the cohorts above. Bioimpedance body composition separates fat from lean mass, which matters when an antidepressant or a sedentary year shifts weight and when BMI understates risk. Heart rate variability adds an autonomic dimension; baseline autonomic measures did not predict improvement in 665 NESDA participants with multisite pain, so it serves as a trended descriptor, not a prognostic score. In older patients whose complaints include memory or processing change, the cognitive assessment and fall prevention workflow documents a separate domain; a cognitive test is not a depression instrument and should not be read as one.

    Standing orders and documentation

    The reproducible version is a standing order that attaches fasting glucose, A1c, a lipid panel with the triglyceride-to-HDL ratio, C-reactive protein and body composition to any positive depression screen in a chronic pain patient, and to any pre-procedure evaluation in a patient with depressive symptoms. The baseline then exists before the antidepressant, the injection or the referral, and a scheduled repeat shows whether a combined plan is moving the terrain. The same results support the documentation that MIPS and quality reporting frameworks already track, and filing them as structured data through getting results into the record keeps them visible to the behavioral clinician and the interventionalist at once. The broader argument is in why metabolic health belongs in a pain practice.

    The limits, stated once

    The evidence is largely observational, the markers are surrogates, and the inflammatory signal describes a subgroup. The practice position stands: mood and metabolism are one system, and small effects that stack are the honest offer. Measure both layers at baseline, treat them together, and remeasure. What happens when that plan leaves the clinic is the subject of referral to diabetes prevention with measurement; patients can read the patient version.

    Frequently asked questions

    How is insulin resistance checked in a pain patient?

    With routine measurements rather than a single test. The cohorts cited here used fasting glucose, HbA1c, HOMA-IR, triglycerides with HDL as a ratio, and waist or waist-hip ratio; prediabetic glycemia and an elevated triglyceride-to-HDL ratio are the practical flags. Body composition adds whether weight is fat or lean mass. Recorded at baseline and repeated on a schedule, these values show whether a combined plan is moving the terrain.

    Is insulin resistance associated with depression?

    Yes, in both directions and prospectively. Depression predicted incident type 2 diabetes at a relative risk of 1.60, and in a Dutch cohort without prior depression, a higher triglyceride-to-HDL ratio predicted first-onset major depression at a hazard ratio of 1.89 and incident prediabetes at 2.66. The cross-sectional association is small and the markers are surrogates. The clinical rationale for cardiometabolic measurement follows the same logic.

    Which laboratory values belong beside a positive depression screen in a pain patient?

    The markers studied are fasting glucose, HbA1c, triglycerides and HDL as a ratio, waist or body composition, and C-reactive protein, which identifies the inflammatory subgroup at thresholds of 3 and 1 mg/L. None of them diagnoses depression; together they describe the terrain the mood disorder and the pain share. Available panels are described under laboratory panels.

    Should mood and metabolic status be documented before an interventional procedure?

    The prospective data support it. Depression score and poor baseline function predicted injection and ablation failure across seven hospitals, obesity reduced relief, and metabolic syndrome raised wound and renal complications after spine surgery. Documentation is not a reason to withhold a procedure that serves as a bridge; it sets expectations and adds the work that fills the window. Reading the results is covered in interpreting the report.

    How should weight change on an antidepressant be monitored?

    With a baseline and a scheduled recheck. In a UK cohort of 294,719 adults, antidepressant use carried a rate ratio of 1.21 for gaining at least 5 percent of body weight, persisting six years or more. Body composition distinguishes fat gain from other change, and fasting glucose tracks the metabolic consequence. Between-visit tracking is outlined in chronic care and between-visit monitoring.

    Where does this fit in an annual wellness visit?

    The annual wellness visit is a structured point for reviewing risk factors, which makes it a practical place to pair a positive mood screen with metabolic measurement in patients who also report chronic pain. Results serve as documentation and trend data rather than an indication by themselves, and they give the next visit a comparison point. Workflow options are in annual wellness visit integration.

    Measure the metabolic half of a positive screen

    Learn how the Measura protocol pairs laboratory panels, body composition and autonomic measures with depression screening in pain patients, with results returned to the ordering physician.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Aaron, R. V., Ravyts, S. G., Carnahan, N. D., Bhattiprolu, K., Harte, N., McCaulley, C. C., Vitalicia, L., Rogers, A. B., Wegener, S. T., & Dudeney, J. (2025). Prevalence of Depression and Anxiety Among Adults With Chronic Pain: A Systematic Review and Meta-Analysis. JAMA Network Open, 8(3), e250268. https://doi.org/10.1001/jamanetworkopen.2025.0268
    • Kan, C., Silva, N., Golden, S. H., Rajala, U., Timonen, M., Stahl, D., & Ismail, K. (2013). A systematic review and meta-analysis of the association between depression and insulin resistance. Diabetes Care, 36(2), 480–9. https://doi.org/10.2337/dc12-1442
    • Mezuk, B., Eaton, W. W., Albrecht, S., & Golden, S. H. (2008). Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care, 31(12), 2383–90. https://doi.org/10.2337/dc08-0985
    • Watson, K. T., Simard, J. F., Henderson, V. W., Nutkiewicz, L., Lamers, F., Nasca, C., Rasgon, N., & Penninx, B. W. J. H. (2021). Incident Major Depressive Disorder Predicted by Three Measures of Insulin Resistance: A Dutch Cohort Study. Am J Psychiatry, 178(10), 914–920. https://doi.org/10.1176/appi.ajp.2021.20101479
    • Osimo, E. F., Baxter, L. J., Lewis, G., Jones, P. B., & Khandaker, G. M. (2019). Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels. Psychol Med, 49(12), 1958–1970. https://doi.org/10.1017/S0033291719001454
    • Gafoor, R., Booth, H. P., & Gulliford, M. C. (2018). Antidepressant utilisation and incidence of weight gain during 10 years’ follow-up: population based cohort study. BMJ, 361, k1951. https://doi.org/10.1136/bmj.k1951
    • Liang, Y., & Booker, C. (2024). Allostatic load and chronic pain: a prospective finding from the national survey of midlife development in the United States, 2004-2014. BMC Public Health, 24(1), 416. https://doi.org/10.1186/s12889-024-17888-1
    • Cohen, S. P., Doshi, T. L., Kurihara, C., Reece, D., Dolomisiewicz, E., Phillips, C. R., Dawson, T., Jamison, D., Young, R., & Pasquina, P. F. (2021). Multicenter study evaluating factors associated with treatment outcome for low back pain injections. Regional Anesthesia and Pain Medicine, 47(2), 89–99. https://doi.org/10.1136/rapm-2021-103247
    • Javeed, S., Benedict, B., Yakdan, S., Saleem, S., Zhang, J. K., Botterbush, K., Frumkin, M. R., Hardi, A., Neuman, B., Kelly, M. P., Steinmetz, M. P., Piccirillo, J. F., Goodin, B. R., Rodebaugh, T. L., Ray, W. Z., & Greenberg, J. K. (2024). Implications of Preoperative Depression for Lumbar Spine Surgery Outcomes: A Systematic Review and Meta-Analysis. JAMA Network Open, 7(1), e2348565. https://doi.org/10.1001/jamanetworkopen.2023.48565
    • Kroenke, K., Bair, M. J., Damush, T. M., Wu, J., Hoke, S., Sutherland, J., & Tu, W. (2009). Optimized antidepressant therapy and pain self-management in primary care patients with depression and musculoskeletal pain: a randomized controlled trial. JAMA, 301(20), 2099–110. https://doi.org/10.1001/jama.2009.723

    Related reading

  • Dr. Gurpreet Singh Padda presenting the title card Nerve or Joint? Pain Speaks Two Languages, The Pained Brain, Chapter 20

    The Sudomotor Test in Mixed Pain: What It Adds and What It Cannot

    Nerve or Joint? Pain Speaks Two Languages | The Pained Brain, Chapter 20

    The Sudomotor Test in Mixed Pain: What It Adds and What It Cannot

    A sudomotor test measures sweat-gland function driven by small autonomic nerve fibers in the hands and feet, an objective look at the small-fiber loss behind many kinds of neuropathic pain. It supports the examination-based grade; it does not locate a focal nerve lesion or name the pain generator.

    Neuropathic pain is graded by examination, not detected by a single test. Objective small-fiber and autonomic measurement belongs beside that grade, as long as nobody expects it to name the generator.

    Neuropathic pain inside a nociceptive diagnosis is common, under-named and treated in the wrong language. Among 473,815 US nursing home residents, coded neuropathic pain ran 14.6 percent, and 28.2 percent of those residents received no treatment for it at all. The sudomotor test is often proposed as the missing objective step, and it has a legitimate place, provided nobody asks it to name the generator. The chapter video, Nerve or Joint? Pain Speaks Two Languages, presents chapter 20 of The Pained Brain by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Dr. KrisJay Fucanan, MD. The graded evidence is in the book companion for chapter 20; the focus here is where objective small-fiber and autonomic measurement belongs in the workup.

    How is neuropathic pain diagnosed?

    The NeuPSIG grading system earns possible from a relevant lesion and a neuroanatomically plausible distribution, probable from sensory signs in that distribution, and definite from a confirmatory test; probable should usually be sufficient to initiate treatment, and negative signs outweigh positive ones. Uptake has been poor: only 56 of 220 clinical studies, 25 percent, used the system, and screening questionnaires are not to be used alone. At the bedside, a cluster of 8 history and examination items reached 72 percent sensitivity and 80 percent specificity for lumbosacral root compression.

    The joint European assessment guideline gives a strong recommendation to DN4 and LANSS and to skin biopsy, a weak one to quantitative sensory testing, and supports neither functional neuroimaging nor nerve blocks for diagnosis. A diagnostic block still has a role in locating a generator for treatment planning; it simply does not grade neuropathic pain.

    How often does nerve pain hide inside a joint or surgical diagnosis?

    In hip osteoarthritis, 29 percent screened possible and 9 percent probable neuropathic-like on painDETECT. After thoracic surgery, persistent postoperative pain ran 38.1 percent across 19,001 patients, with a neuropathic component in 33.0 percent of those. Before knee arthroplasty in two cohorts of 524 patients, an unclear painDETECT band carried odds of 2.19 and a neuropathic-like band 2.83 for moderate-to-severe pain at a year; a Korean cohort of 148 using DN4 found no effect, with only about 22 neuropathic patients. Across a Swedish national registry of 6,579,612 adults, first-year pain medication use after a lower-limb nerve injury carried a relative risk of 5.60.

    The social driver is the default pathway. A nociceptive label arrives with a nociceptive prescription and a procedural referral, and nobody is assigned to re-grade the pain when the response disappoints.

    What does a sudomotor test measure?

    Measura [Cardiometabolic and Autonomic Health Analysis] is a testing service reporting to the ordering physician; it does not diagnose disease on its own and does not treat. Sudomotor testing measures sweat-gland function mediated by small autonomic fibers in the distal limbs, an objective window on the same small-fiber population whose loss drives many neuropathic phenotypes. Cardiac autonomic reflex tests and broader autonomic nervous system testing characterize cardiovagal and sympathetic function when the history suggests wider autonomic involvement.

    Three limits should be stated once. First, none of these tests locates a focal lesion: a superior cluneal neuropathy, meralgia paresthetica or an infrapatellar saphenous branch injury will not declare itself on a distal sweat measurement. Second, Measura cannot diagnose a joint generator or exclude one; that remains examination and diagnostic injection. Third, small-fiber structure does not grade pain. Skin biopsy, the Level A confirmatory test and a different test done elsewhere, does not correlate with pain intensity, and intraepidermal density separated painful from painless diabetic neuropathy only at a standardized 0.31 across 664 patients. Read an abnormal sudomotor result as evidence of a substrate, not as a pain diagnosis.

    What changes when a sudomotor test is abnormal?

    Phenotype, then drug. Cluster analysis of 902 patients with peripheral neuropathic pain found sensory loss in 42 percent, thermal hyperalgesia in 33 percent and mechanical hyperalgesia in 24 percent. Oxcarbazepine’s number needed to treat was 3.9 in the irritable nociceptor phenotype against 13 without it, with a barely significant interaction; a phenotype-stratified lacosamide trial found no difference and closed early. In 30 patients with painful diabetic neuropathy, conditioned pain modulation correlated with duloxetine response at 0.628. Documented small-fiber loss moves a patient toward the neuropathic side of that ledger and toward the first-line agents built for it.

    Metabolism, alongside. In recordings from people with diabetes, 79 percent of sampled C-fibers were pathologically altered, and 72 percent of nociceptors fired spontaneously in painful neuropathy against 15 percent in painless neuropathy. A small-fiber finding without laboratory panels for glycemia is half a result. Normative intraepidermal density also falls by 1.35 fibers per millimeter every five years, so age belongs in any interpretation.

    Falls. Distal small-fiber and autonomic dysfunction belong in the same conversation as balance in older patients. Pair a positive result with the cognitive assessment and fall prevention workflow rather than filing it alone.

    Who should get a sudomotor test?

    • Pain labeled as a joint or disc problem with burning quality, allodynia or a sensory deficit on examination.
    • Persistent pain after arthroplasty or thoracic surgery that has not responded to nociceptive treatment.
    • Patients with diabetes or a prediabetic A1c reporting distal burning or numbness.
    • Preoperative arthroplasty candidates in an unclear or neuropathic-like painDETECT band.

    Selection criteria are summarized under who to test, and results support documentation in MIPS and quality reporting. The humility belongs here too: Dr. Padda has said he has treated a nerve in the language of a joint, as most of us have. The upstream error, choosing clinics and workups by the wrong measure, is taken up in comprehensive pain assessment. Patients can read the patient version.

    Frequently asked questions

    Does a sudomotor test diagnose small-fiber neuropathy?

    It provides objective evidence about sweat-gland function mediated by small fibers, which supports the clinical picture, but it is not the Level A confirmatory standard; that is distal leg skin biopsy, done elsewhere. Interpret it with the examination, glycemic status and age. It does not grade pain severity or identify a focal lesion. Reading results in context is covered in interpreting the report.

    Can objective testing distinguish neuropathic from nociceptive pain?

    No validated test separates the two in a clinic. Imaging signatures classify patients against healthy controls rather than by mechanism, and structural small-fiber measures show only modest group differences between painful and painless neuropathy. The grade still comes from history and examination, and a diagnostic block locates a generator. Testing documents the substrate. The wider argument for measurement is in clinical rationale.

    Should knee arthroplasty candidates be screened for neuropathic-like pain?

    The larger evidence suggests value. Across two cohorts of 524 patients, a neuropathic-like painDETECT band before surgery carried odds of 2.83 for moderate-to-severe pain at one year and a lower Oxford Knee Score, while a smaller Korean cohort using DN4 did not replicate it. Screening before the date is booked sets expectations. Specialty use is outlined in specialty applications.

    Which patients belong on a standing order for small-fiber and autonomic testing?

    Reasonable candidates are patients with diabetes or prediabetes and distal burning, persistent postsurgical pain with neuropathic features, and pain carrying a joint or disc label that has not responded to nociceptive treatment. A standing order keeps the decision out of a crowded visit and pairs the test with glycemic labs. Templates are described in standing orders for screening.

    How should results be documented?

    File them as structured data with the examination findings and the neuropathic pain grade, so the substrate stays visible when later procedure and medication notes are written. Record glycemic status and age beside any small-fiber result, since both change interpretation, and repeat measurement shows the direction of travel. The mechanics are in getting results into the record.

    What is the best test for small-fiber neuropathy?

    The confirmatory Level A test is a skin biopsy from the lower leg, done elsewhere. A sudomotor test is an objective, noninvasive look at the same small-fiber population through sweat-gland function, and it supports the clinical picture. Neither one grades pain. The neuropathic pain grade still comes from the history and a hands-on examination.

    Can a sudomotor test find a pinched or injured nerve?

    No. A sudomotor test reads sweat-gland function in the hands and feet, so a single injured nerve elsewhere will not show up on it. A superior cluneal neuropathy, meralgia paresthetica or an injured saphenous branch below the knee needs an examination and, where indicated, a diagnostic injection. The test also cannot diagnose or exclude a painful joint.

    Does age change how a small-fiber result is read?

    Yes. Normal small-fiber density in the skin falls by 1.35 fibers per millimeter every five years, so the same reading means something different at different ages. Age and blood sugar status belong beside any small-fiber or sudomotor result, and repeat measurement shows the direction of travel better than a single reading.

    Add objective small-fiber data to the pain workup

    Learn how the Measura protocol pairs sudomotor, autonomic and metabolic testing with the neuropathic pain workup, with results returned to the ordering physician.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Mbrah, A. K., Nunes, A. P., Hume, A. L., Zhao, D., Jesdale, B. M., Bova, C., & Lapane, K. L. (2022). Prevalence and treatment of neuropathic pain diagnoses among U.S. nursing home residents. Pain, 163(7), 1370-1377. https://doi.org/10.1097/j.pain.0000000000002525
    • Finnerup, N. B., Haroutounian, S., Kamerman, P., Baron, R., Bennett, D. L. H., Bouhassira, D., Cruccu, G., Freeman, R., Hansson, P., Nurmikko, T., Raja, S. N., Rice, A. S. C., Serra, J., Smith, B. H., Treede, R. D., & Jensen, T. S. (2016). Neuropathic pain: an updated grading system for research and clinical practice. Pain, 157(8), 1599–1606. https://doi.org/10.1097/j.pain.0000000000000492
    • Truini, A., Aleksovska, K., Anderson, C. C., Attal, N., Baron, R., Bennett, D. L., Bouhassira, D., Cruccu, G., Eisenberg, E., Enax-Krumova, E., Davis, K. D., Di Stefano, G., Finnerup, N. B., Garcia-Larrea, L., Hanafi, I., Haroutounian, S., Karlsson, P., Rakusa, M., Rice, A. S. C., … Veluchamy, A. (2023). Joint European Academy of Neurology-European Pain Federation-Neuropathic Pain Special Interest Group of the International Association for the Study of Pain guidelines on neuropathic pain assessment. European Journal of Neurology, 30(8), 2177-2196. https://doi.org/10.1111/ene.15831
    • Mistry, J., Heneghan, N. R., Noblet, T., Falla, D., & Rushton, A. (2020). Diagnostic utility of patient history, clinical examination and screening tool data to identify neuropathic pain in low back related leg pain: a systematic review and narrative synthesis. BMC Musculoskeletal Disorders, 21(1), 532. https://doi.org/10.1186/s12891-020-03436-6
    • Wall, A. J. W., Leyland, K. M., Kiran, A., Arden, N. K., Cooper, C., Wanigasekera, V., Javaid, M. K., Price, A. J., Tracey, I. M. C., & Irani, A. (2025). PainDETECT as a Potential Tool for Personalized Medicine: Predicting Outcome One Year After Knee Arthroplasty. Mayo Clinic Proceedings: Innovations, Quality & Outcomes, 9(5), 100649. https://doi.org/10.1016/j.mayocpiqo.2025.100649
    • Lauria, G., Hsieh, S. T., Johansson, O., Kennedy, W. R., Leger, J. M., Mellgren, S. I., Nolano, M., Merkies, I. S. J., Polydefkis, M., Smith, A. G., Sommer, C., & Valls-Solé, J. (2010). European Federation of Neurological Societies/Peripheral Nerve Society guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. European Journal of Neurology, 17(7), 903-912, e44-e49. https://doi.org/10.1111/j.1468-1331.2010.03023.x
    • Gad, H. Y., Devigili, G., Merkies, I., Gilron, I., MacDonald, R., Lauria, G., & Malik, R. A. (2026). Corneal confocal microscopy and skin biopsy to differentiate painful from painless diabetic neuropathy: A systematic review with multiple meta-analyses. European Journal of Neurology, 33(3), e70576. https://doi.org/10.1111/ene.70576
    • Baron, R., Maier, C., Attal, N., Binder, A., Bouhassira, D., Cruccu, G., Finnerup, N. B., Haanpää, M., Hansson, P., Hüllemann, P., Jensen, T. S., Freynhagen, R., Kennedy, J. D., Magerl, W., Mainka, T., Reimer, M., Rice, A. S. C., Segerdahl, M., Serra, J., … Treede, R. D. (2017). Peripheral neuropathic pain: a mechanism-related organizing principle based on sensory profiles. Pain, 158(2), 261–272. https://doi.org/10.1097/j.pain.0000000000000753
    • Demant, D. T., Lund, K., Vollert, J., Maier, C., Segerdahl, M., Finnerup, N. B., Jensen, T. S., & Sindrup, S. H. (2014). The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: A randomised, double-blind, placebo-controlled phenotype-stratified study. Pain, 155(11), 2263–2273. https://doi.org/10.1016/j.pain.2014.08.014
    • Becker, A. K., Babes, A., Düll, M. M., Khalil, M., Kender, Z., Gröner, J., Namer, B., Reeh, P. W., & Sauer, S. K. (2023). Spontaneous activity of specific C-nociceptor subtypes from diabetic patients and mice: Involvement of reactive dicarbonyl compounds and (sensitized) transient receptor potential channel A1. Journal of the Peripheral Nervous System, 28(2), 202–225. https://doi.org/10.1111/jns.12546

    Related reading

  • Dr. Gurpreet Singh Padda presenting the title card Kindness Is the Baseline, Not the Achievement, The Pained Brain, Chapter 19

    Comprehensive Pain Assessment: Measuring What the Short Visit Skips

    Kindness Is the Baseline, Not the Achievement | The Pained Brain, Chapter 19

    Comprehensive Pain Assessment: Measuring What the Short Visit Skips

    A comprehensive pain assessment finds the pain generator by examination, then screens the terrain: A1c for glycemia, sleep apnea, and depression and anxiety. All are common in chronic pain, and all are easy to miss in a short visit graded on satisfaction.

    Satisfaction scores reward the fulfilled request. The findings that change a chronic pain plan rarely surface in a visit organized around that score.

    A chronic pain practice is graded on satisfaction, and satisfaction is earned by the fulfilled request. The workup that changes the plan, the prediabetic A1c, the untested apnea, the hip behind the back pain, earns nothing on that scale because the patient never sees it happen. The chapter video, Kindness Is the Baseline, Not the Achievement, presents chapter 19 of The Pained Brain by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Dr. KrisJay Fucanan, MD. Study-level detail and limits are in the book companion for chapter 19; the focus here is what a comprehensive pain assessment should measure and how to make that reproducible in primary care, pain, endocrinology and geriatric practice.

    Do patient satisfaction scores get in the way of a full pain workup?

    In 1,319 family medicine visits, denying a patient’s request cost satisfaction by request type: 19.75 percentile points for a referral, 10.72 for pain medication and 9.19 for a laboratory test. The last figure is the non-obvious one. A requested lab that is refused is penalized; a lab nobody thought to discuss is invisible. The score therefore punishes saying no and is blind to not looking. In a survey of 155 self-selected physicians in one state, 59 percent reported compensation tied to satisfaction ratings, with a 3.9 percent response rate that limits how far the finding travels. The structural driver is plain enough: the metric rewards the visible transaction, and terrain screening is not visible.

    How often does a second look change the pain diagnosis?

    Extrapolated from three US observational studies, about 5.08 percent of adults experience an outpatient diagnostic error each year. Among 286 primary care referrals to a tertiary center, selected for diagnostic uncertainty, the referral diagnosis matched the final diagnosis in 12 percent, was refined in 66 percent and was distinctly different in 21 percent. In a single surgeon’s consecutive series of 200 back pain patients, 17.5 percent had hip or sacroiliac pathology alongside the spine, 8 percent had it without spine pathology, and 10 percent remained undefined after the workup.

    None of those generators is found by a measurement service. They are found by examination and, where indicated, a diagnostic injection. The terrain is a separate question, and it is where objective testing earns its place.

    What does screening find in people with chronic pain?

    Glycemia. Point-of-care A1c in 84 hand clinic patients with carpal tunnel syndrome, trigger finger, Dupuytren’s contracture or De Quervain’s disease found 58.3 percent in the prediabetic range and 4.8 percent in the diabetic range; 43.4 percent of those with abnormal values had no primary care provider. The conditions were chosen for their known diabetes association, so the yield transfers to that presentation rather than to all pain.

    Sleep-disordered breathing. Among opioid-treated Canadian pain clinic patients who completed polysomnography, 58.8 percent had sleep apnea, and each one-unit rise in STOP-Bang raised the odds of moderate-to-severe disease by 70 percent. In 90 consecutive Danish patients with high-impact chronic pain, 51.1 percent had obstructive apnea and 31.1 percent moderate or severe disease; Berlin ran 78.6 percent sensitivity and 45.2 percent specificity, STOP-BANG 71.4 and 58.1, and pain, disability and sleepiness did not distinguish the patients with apnea.

    Mood and autoimmunity. Pooled across 376 studies, clinically significant depressive and anxiety symptoms ran 39.3 and 40.2 percent, rising to 54.0 and 55.5 percent in fibromyalgia samples. Thyroid peroxidase antibody positivity carried an odds ratio of 3.41 in fibromyalgia across five small case-control studies.

    Low-yield tests. After full adjustment in 349,221 UK adults, vitamin D status carried odds ratios of 1.01 or lower for regional musculoskeletal pain; only deficiency below 25.0 nmol/L held a signal for widespread pain, at 1.26. Celiac screening in 62 Brazilian fibromyalgia patients found no cases. A comprehensive pain assessment is not every test; it is the tests the presentation points to.

    Who needs a comprehensive pain assessment?

    • Chronic musculoskeletal or tendon-region pain in a patient without a recent A1c, or whose last value sat in the prediabetic band.
    • Patients on long-term opioid therapy, who warrant formal sleep testing rather than reliance on a questionnaire.
    • Patients carrying a fibromyalgia label, where mood screening and the metabolic panel belong in the same encounter.
    • Candidates for neuromodulation, since depression predicted first-year spinal cord stimulator explant at 1.39 in claims data.
    • Pain that has absorbed repeated procedures without a documented diagnosis.

    Practice-level criteria are summarized under selection criteria.

    Where Measura fits and where it does not

    Measura [Cardiometabolic and Autonomic Health Analysis] is a testing service that reports to the ordering physician; it does not diagnose disease on its own and it does not treat. Two measurements carry this pathway: laboratory panels, which put A1c and fasting insulin in the chart, and bioimpedance body composition, which shows whether weight is muscle or adipose tissue. In older patients with chronic pain, cognitive assessment fits the same encounter, with the cognitive assessment and fall prevention workflow holding the two records side by side. Polysomnography, validated depression instruments and diagnostic blocks sit outside the service and should be ordered in parallel.

    Metabolic health is the exception, not the default. The metabolically healthy share of American adults was under 12.2 percent on NHANES 2009–2016 and fell under 7 percent on the stricter criteria applied after 2021. In our clinic, under 1 percent of chronic pain patients qualify; that is a practice-reported figure from our own population rather than a trial outcome, and individual results vary. Dr. Padda’s own confession is that for years he read a borderline A1c as reassurance. That is the error a standing order is designed to remove.

    Standing orders, documentation and follow-up in numbers

    A standing order that attaches metabolic labs and body composition to new chronic pain referrals removes the decision from a crowded visit. The same results support cardiometabolic and cognitive documentation in MIPS and quality reporting as quality documentation rather than as an indication in themselves.

    Follow-up needs its own numbers. Across 116 randomized trials and 49,785 patients, feeding patient-reported outcomes back to clinicians improved communication at a standardized 0.36, diagnosis and notation at a risk ratio of 1.73, and disease control at 1.25, while pain itself moved 0.00. Measurement is how a practice learns whether a plan worked, not the plan. Agree on the target up front: IMMPACT counts 30 percent as moderate and 50 percent as substantial improvement, and 110 patients defining success named 56 percent. Outcome tracking is described under what changes for the patient. The related tendon referral pathway is in tendinopathy as a metabolic signal, and patients can read the patient version.

    Frequently asked questions

    What belongs in a comprehensive pain assessment beyond the pain score?

    A generator-focused examination, a mood screen, a sleep history with a low threshold for polysomnography in opioid-treated patients, and a metabolic panel including A1c. Add function and a documented target for improvement. The yield is highest where the presentation points: tendon and entrapment syndromes toward glycemia, fibromyalgia toward mood and thyroid autoimmunity. The broader reasoning is set out in clinical rationale.

    Should chronic pain patients on opioids be referred for a sleep study?

    The data support a low threshold. In opioid-treated pain clinic patients who completed polysomnography, 58.8 percent had sleep apnea, and in a high-impact chronic pain cohort the Berlin and STOP-BANG questionnaires missed a substantial share. Polysomnography is outside the Measura service and is ordered separately. Specialty-specific pathways are outlined under specialty applications.

    Which screening tests have low yield in chronic pain?

    Two published negatives are useful. Vitamin D did not independently predict regional musculoskeletal pain after confounder adjustment in 349,221 UK adults, and celiac screening in 62 fibromyalgia patients found no cases. Ordering what the presentation points to, and documenting why other tests were not ordered, keeps the workup defensible. Reading results in context is covered in interpreting the report.

    How do Measura results reach the chart?

    Results return to the ordering physician, who interprets them and decides on management. They can be filed as structured data so that the metabolic and body composition baseline stays visible when later procedure, therapy and behavioral health notes arrive, and so repeat values can be compared over time. The mechanics are described in getting results into the record.

    Can terrain screening be built into an annual wellness visit?

    Yes, as documentation. Glycemic, body composition and cognitive results fit the structure an annual wellness visit already uses, and they give a chronic pain patient a measured baseline outside the pain visit. The visit does not become a pain evaluation; it becomes the place where the terrain is recorded. Workflow is outlined in annual wellness visit integration.

    How common are depression and anxiety in chronic pain?

    Common enough that a comprehensive assessment should screen for both. Pooled across 376 studies of adults with chronic pain, 39.3 percent had clinically significant depressive symptoms and 40.2 percent had anxiety symptoms. In fibromyalgia samples the figures rose to 54.0 and 55.5 percent. Depression also predicted first-year spinal cord stimulator removal in claims data, which matters before any neuromodulation decision.

    How common is sleep apnea in people with chronic pain?

    In 90 consecutive patients with high-impact chronic pain, 51.1 percent had obstructive sleep apnea and 31.1 percent had moderate or severe disease. Pain, disability and sleepiness did not set those patients apart, and the Berlin and STOP-BANG questionnaires missed a real share of cases. That is why opioid-treated patients warrant a formal sleep study rather than a questionnaire alone.

    What does Measura test as part of a pain assessment?

    Two measurements carry this pathway: laboratory panels that put A1c and fasting insulin in the chart, and bioimpedance body composition that shows whether weight is muscle or fat. In older patients, cognitive assessment fits the same visit. Sleep studies, depression instruments and diagnostic blocks sit outside the service and are ordered in parallel. Every result goes to the ordering physician.

    Make the terrain part of every pain workup

    Learn how the Measura protocol adds metabolic labs, body composition and cognitive assessment to chronic pain referrals, with results returned to the ordering physician.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Jerant, A., Fenton, J. J., Kravitz, R. L., Tancredi, D. J., Magnan, E., Bertakis, K. D., & Franks, P. (2018). Association of Clinician Denial of Patient Requests With Patient Satisfaction. JAMA Internal Medicine, 178(1), 85–91. https://doi.org/10.1001/jamainternmed.2017.6611
    • Zgierska, A., Rabago, D., & Miller, M. M. (2014). Impact of patient satisfaction ratings on physicians and clinical care. Patient Preference and Adherence, 8, 437–446. https://doi.org/10.2147/PPA.S59077
    • Heiting, C., Wickes, C. B., Katakam, S., Herrera, C., Li, B., Intravia, J., Nolan, J. E., & Nellans, K. W. (2026). Occurrence of Undiagnosed Diabetes Mellitus With Musculoskeletal Disorders of the Upper Extremity: Prospective Screening With Point-of-Care Haemoglobin A1c Fingerstick Testing. Musculoskeletal Care, 24(3), e70256. https://doi.org/10.1002/msc.70256
    • Chung, F., Wong, J., Bellingham, G., Lebovic, G., Singh, M., Waseem, R., Peng, P., George, C. F. P., Furlan, A., Bhatia, A., Clarke, H., Juurlink, D. N., Mamdani, M. M., Horner, R., Orser, B. A., & Ryan, C. M. (2019). Predictive factors for sleep apnoea in patients on opioids for chronic pain. BMJ Open Respiratory Research, 6(1), e000523. https://doi.org/10.1136/bmjresp-2019-000523
    • Larsen, D. B., Bendix, L., Abeler, K., Petersen, K. K., Sprehn, M., Bruun, K. D., Blichfeldt-Eckhardt, M. R., & Vaegter, H. B. (2021). Obstructive sleep apnea is common in patients with high-impact chronic pain – an exploratory study from an interdisciplinary pain center. Scandinavian Journal of Pain, 22(1), 106–117. https://doi.org/10.1515/sjpain-2021-0112
    • Aaron, R. V., Ravyts, S. G., Carnahan, N. D., Bhattiprolu, K., Harte, N., McCaulley, C. C., Vitalicia, L., Rogers, A. B., Wegener, S. T., & Dudeney, J. (2025). Prevalence of Depression and Anxiety Among Adults With Chronic Pain: A Systematic Review and Meta-Analysis. JAMA Network Open, 8(3), e250268. https://doi.org/10.1001/jamanetworkopen.2025.0268
    • Xie, Y., Farrell, S. F., Armfield, N., & Sterling, M. (2024). Serum Vitamin D and Chronic Musculoskeletal Pain: A Cross-Sectional Study of 349,221 Adults in the UK. The Journal of Pain, 25(9), 104557. https://doi.org/10.1016/j.jpain.2024.104557
    • Sembrano, J. N., & Polly, D. W. (2009). How often is low back pain not coming from the back? Spine (Phila Pa 1976), 34(1), E27-E32. https://doi.org/10.1097/BRS.0b013e31818b8882
    • Gibbons, C., Porter, I., Gonçalves-Bradley, D. C., Stoilov, S., Ricci-Cabello, I., Tsangaris, E., Gangannagaripalli, J., Davey, A., Gibbons, E. J., Kotzeva, A., Evans, J., van der Wees, P. J., Kontopantelis, E., Greenhalgh, J., Bower, P., Alonso, J., & Valderas, J. M. (2021). Routine provision of feedback from patient-reported outcome measurements to healthcare providers and patients in clinical practice. Cochrane Database of Systematic Reviews, 10(10), CD011589. https://doi.org/10.1002/14651858.CD011589.pub2
    • Van Such, M., Lohr, R., Beckman, T., & Naessens, J. M. (2017). Extent of diagnostic agreement among medical referrals. Journal of Evaluation in Clinical Practice, 23(4), 870–874. https://doi.org/10.1111/jep.12747

    Related reading

  • Dr. Gurpreet Singh Padda presenting the title card for The Pained Brain, Chapter 18

    Quality-Adjusted Life Years: Measuring What Spine Care Returns

    The Four-Dollar Bottle Costs the Years | The Pained Brain, Chapter 18

    Quality-Adjusted Life Years: Measuring What Spine Care Returns

    A quality-adjusted life year counts a year in full health as one and a year at half of full health as half, and spine trials use it to express what an intervention returns. Applied to a referral, it only means something when a baseline health utility score is recorded before the referral.

    Every spine trial that reports value reports it in years of health. Few referral letters record the baseline those years are counted from, or the metabolic terrain that decides whether they accrue.

    The quality-adjusted life year (QALY) is the unit most spine trials use to express what an intervention returns: a year in full health counts as one, and a year at half of full health counts as half. It is usually quoted in policy work, but underneath it sits a clinical measurement, the health utility score, and that score is rarely recorded before a referral. The video for Chapter 18 of The Pained Brain, by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Dr. KrisJay Fucanan, MD, works through the spine evidence in those units; study-level detail and limits are in the Chapter 18 book companion. Here the unit is treated as what it is for the ordering physician: an outcome measure, with a baseline, a horizon and blind spots.

    What is the health utility score inside a QALY?

    US population norms place mean utility at 0.824 for adults aged 65 to 74. A Danish national catalog put dorsalgia at 0.619 and fibromyalgia at 0.490, lower than dementia at 0.546, and listed both among the conditions with the largest modeled loss of quality of life. Among 1,194 patients scheduled for degenerative lumbar spine surgery in Singapore, mean preoperative utility was 0.43, with 93.6 percent reporting pain or discomfort. Chronic pain removes a third to a half of a year of health from each year lived with it.

    The instrument has a known weakness: the value set changes the number. Among 34,254 Swedish osteoarthritis patients, the same people scored 0.792 on a Swedish experience-based value set and 0.605 on a UK hypothetical one. Utilities borrowed across countries are unreliable. Recorded in one practice, with one instrument, repeated over time, they become a usable longitudinal outcome.

    Why does the starting utility score decide the benefit?

    The clearest evidence that starting utility predicts surgical return comes from arthroplasty. In a German multicenter study of 4,182 hip and 3,645 knee replacements, the minimal clinically important change in utility was 0.2, and patients starting above 0.7 for a hip or 0.6 for a knee gained no meaningful benefit. Those thresholds are decision aids from joint surgery, not spine rules, but the principle transfers: an operation cannot restore utility a patient has not lost. Decision support changes real choices, too. When a large health system introduced decision aids for hip and knee osteoarthritis, hip replacements fell 26 percent and knee replacements 38 percent. Neither finding can be applied to an individual unless a baseline exists in the chart before the referral.

    What do spine trials show when patients are followed longer?

    Two-year spine outcomes and eight-year outcomes are different findings. In the SPORT stenosis cohort, the surgical advantage in years three and four was reduced by approximately 75 percent from the first two years, and no significant effect of surgery remained in years six through eight. By then, 70 percent randomized to surgery and 52 percent randomized to non-operative care had been operated on, which dilutes intention-to-treat contrasts in both directions. The spondylolisthesis cohort analyzed as treated, by contrast, kept its surgical advantage at eight years.

    The fusion question is where the unit is most informative. At two years, adding fusion to a stenosis decompression added −0.01 quality-adjusted life years. For chronic low back pain without a slip, fusion against intensive rehabilitation produced a 0.068 difference that was not significant, and at eleven years the fusion advantage on a 100-point disability scale was −0.7 points. Pooled, fusion for degenerative disc disease carried 21.46 times the complication rate of non-operative care. Randomized trials in Sweden and Norway found decompression alone comparable or non-inferior; an American trial reported a reoperation rate of 14 percent with fusion versus 34 percent without.

    What can a QALY miss?

    A utility score can miss a real clinical gain. In 325 older adults with insomnia and osteoarthritis pain, six telephone sessions of cognitive behavioral therapy lowered insomnia severity and joint symptoms by 2.6 points each and added 89 nights without insomnia over twelve months, yet the utility difference was −0.01. Lifetime gains are also often projected rather than measured: the 0.06 quality-adjusted life years in the British diabetes remission trial were driven by modeled life expectancy, not measured two-year utility. The practical conclusion is to pair utility with measures that move faster and are harder to dispute, namely function, body composition, metabolic markers and cognition.

    Terrain as a measurable predictor

    The patient at the center of the video had a lumbar MRI in the second week of her pain and no hemoglobin A1c in four years. When it was drawn, it was 6.4. In a series of 678 posterolateral fusions for degenerative spondylolisthesis, age did not remain a significant predictor of medical complications after adjustment, while anesthesia risk score and body mass index did. The lifestyle arm of the Diabetes Prevention Program cut diabetes incidence by 34 percent, and in knee osteoarthritis with class III obesity, a modeled gastric bypass strategy lowered opioid use from 13 to 4 percent. Those are two biological drivers, insulin resistance and adipose mass, plus a structural one: care pathways that begin with an image or an opioid. In a veterans cohort, an opioid as the opening treatment in place of physical therapy was associated with 1.69-fold odds of spine surgery inside one year and 17.8 times the odds of chronic opioid use. The book is candid that early conservative care is not a guaranteed win; in the randomized trial, the early physical therapy benefit stayed below the threshold of clinical importance.

    Measura [Cardiometabolic and Autonomic Health Analysis] is a testing service; it does not read imaging or recommend surgery. For a patient headed toward a spine referral it documents:

    Workflow: blood before the scan

    The sequence the book argues for is blood before scan, block before burn, bridge before fusion, with named exceptions: cauda equina syndrome is decompressed within 48 hours, and a herniated disc that has failed everything goes to the surgeon promptly. For the rest, a standing order can attach metabolic labs, body composition and a baseline utility instrument to new chronic back pain referrals before advanced imaging, so the first data point is the terrain. The annual wellness visit is a natural home for that baseline in older patients, and filing results as discrete data keeps them visible when the surgical consult returns. How a dose total displaced the patient in pain care is examined in morphine milligram equivalents as a risk variable.

    Frequently asked questions

    What is a quality-adjusted life year in clinical terms?

    It weights time by a health utility score, so one year in full health counts as one and a year at half of full health counts as half. The utility comes from a patient-completed instrument scored against a population value set, which means the same patient can score differently under different value sets. The measurement logic behind recording baselines is summarized in the clinical rationale.

    Does baseline utility predict benefit from surgery?

    In hip and knee arthroplasty it does: patients starting above 0.7 for a hip or 0.6 for a knee gained no meaningful improvement, against a minimal important change of 0.2. Comparable spine thresholds are not established, but the principle argues for recording utility before any referral. What that record changes downstream is described in what changes for the patient.

    Why do two-year and eight-year spine results disagree?

    Early advantages can fade while crossover accumulates. In SPORT stenosis, the surgical advantage shrank by about 75 percent in years three and four and was no longer significant in years six through eight, while most patients in both arms had eventually been operated on. Serial measurement between visits captures that trajectory, as outlined in chronic care and between-visit monitoring.

    Which patients should have metabolic measurement before a spine referral?

    Patients with an elevated body mass index, suspected insulin resistance or prediabetes, long-standing pain, or an opioid started early in the course are reasonable candidates, because body mass index and anesthesia risk predicted complications after fusion where age did not. Distal neuropathic symptoms add small-fiber testing. Practice-level criteria are in selection criteria.

    Which spine presentations should bypass the conservative sequence?

    Cauda equina syndrome, in which operating inside 48 hours was associated with an odds ratio near 2.3 for urinary recovery; acute traumatic central cord syndrome, where early decompression improved motor scores and halved complications; and a herniated disc that has failed conservative care. Degenerative cervical myelopathy is a useful counter-case, since delayed presentation still did well surgically. Specialty uses of measurement are in specialty applications.

    How is a QALY calculated?

    Each year lived is weighted by a health utility score, where a year in full health counts as one and a year at half of full health counts as half, and the weighted years are added together. The utility comes from a patient-completed instrument scored against a population value set, and the value set changes the result: the same Swedish osteoarthritis patients scored 0.792 on one value set and 0.605 on another.

    What is a good QALY score?

    A QALY is a count of years, so the useful comparison is the utility score behind it. US population norms place adults aged 65 to 74 at 0.824. A Danish national catalog put dorsalgia, chronic back pain, at 0.619, and patients scheduled for degenerative lumbar spine surgery in Singapore averaged 0.43. The patient’s own score, recorded before a referral and repeated with the same instrument, is the number that shows change.

    What are examples of QALYs in spine care?

    At two years, adding fusion to a stenosis decompression added −0.01 quality-adjusted life years. For chronic low back pain without a slipped vertebra, fusion against intensive rehabilitation produced a 0.068 difference that was not significant. Outside the spine, the 0.06 quality-adjusted life years in the British diabetes remission trial were driven by modeled life expectancy rather than measured two-year utility, which is why the horizon behind any figure matters.

    Put the baseline in the chart first

    See how the Measura protocol adds metabolic, body composition and cognitive baselines ahead of spine referrals, with results returned to the ordering physician.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Jiang, R., Janssen, M. F. B., & Pickard, A. S. (2021). US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples. Quality of Life Research, 30(3), 803–816. https://doi.org/10.1007/s11136-020-02650-y
    • Hvidberg, M. F., Petersen, K. D., Davidsen, M., Witt Udsen, F., Frølich, A., Ehlers, L., & Alava, M. H. (2023). Catalog of EQ-5D-3L Health-Related Quality-of-Life Scores for 199 Chronic Conditions and Health Risks in Denmark. MDM Policy & Practice, 8(1), 23814683231159023. https://doi.org/10.1177/23814683231159023
    • Li, X., Chern, C. W. J., Teo, A. Q. A., Tan, J. H. J., Vasan Thakumar, A., Luo, N., Hey, H. W. D., & Cheng, L. J. (2026). Factors associated with preoperative health-related quality of life in patients undergoing lumbar spine surgery: a multi-ethnic Asian cohort. Quality of Life Research, 35(6). https://doi.org/10.1007/s11136-026-04257-1
    • Langenberger, B., Steinbeck, V., & Busse, R. (2024). Who Benefits From Hip Arthroplasty or Knee Arthroplasty? Preoperative Patient-reported Outcome Thresholds Predict Meaningful Improvement. Clinical Orthopaedics and Related Research, 482(5), 867–881. https://doi.org/10.1097/CORR.0000000000002994
    • Tosteson, A. N. A., Tosteson, T. D., Lurie, J. D., Abdu, W., Herkowitz, H., Andersson, G., Albert, T., Bridwell, K., Zhao, W., Grove, M. R., Weinstein, M. C., & Weinstein, J. N. (2011). Comparative effectiveness evidence from the spine patient outcomes research trial: surgical versus nonoperative care for spinal stenosis, degenerative spondylolisthesis, and intervertebral disc herniation. Spine, 36(24), 2061–2068. https://doi.org/10.1097/BRS.0b013e318235457b
    • Lurie, J. D., Tosteson, T. D., Tosteson, A., Abdu, W. A., Zhao, W., Morgan, T. S., & Weinstein, J. N. (2015). Long-term outcomes of lumbar spinal stenosis: eight-year results of the Spine Patient Outcomes Research Trial (SPORT). Spine, 40(2), 63–76. https://doi.org/10.1097/BRS.0000000000000731
    • Rivero-Arias, O., Campbell, H., Gray, A., Fairbank, J., Frost, H., & Wilson-MacDonald, J. (2005). Surgical stabilisation of the spine compared with a programme of intensive rehabilitation for the management of patients with chronic low back pain: cost utility analysis based on a randomised controlled trial. BMJ, 330(7502), 1239. https://doi.org/10.1136/bmj.38441.429618.8F
    • Yeung, K., Zhu, W., McCurry, S. M., Von Korff, M., Wellman, R., Morin, C. M., & Vitiello, M. V. (2022). Cost-effectiveness of telephone cognitive behavioral therapy for osteoarthritis-related insomnia. Journal of the American Geriatrics Society, 70(1), 188–199. https://doi.org/10.1111/jgs.17469
    • Aimar, E., Iess, G., Mezza, F., Gaetani, P., Messina, A. L., Todesca, A., Tartara, F., & Broggi, G. (2022). Complications of degenerative lumbar spondylolisthesis and stenosis surgery in patients over 80 s: comparative study with over 60 s and 70 s. Experience with 678 cases. Acta Neurochir (Wien), 164(3), 923-931. https://doi.org/10.1007/s00701-022-05118-9
    • Schmidt, C., Borgia, M., Zhang, T., Gochyyev, P., Shireman, T. I., & Resnik, L. (2023). Initial treatment approaches and healthcare utilization among veterans with low back pain: a propensity score analysis. BMC Health Serv Res, 23(1), 275. https://doi.org/10.1186/s12913-023-09207-y

    Related reading

  • Dr. Gurpreet Singh Padda presenting the title card A Dose Is Not a Diagnosis, The Pained Brain, Chapter 17

    Morphine Milligram Equivalents Are Not a Risk Assessment

    A Dose Is Not a Diagnosis | The Pained Brain, Chapter 17

    Morphine Milligram Equivalents Are Not a Risk Assessment

    A morphine milligram equivalent total is a screening flag, not a risk assessment. In a Medicare cohort, federal dose-based measures captured 29.29 percent of overdose episodes against 90.57 percent for models that weighed dose with other predictors, so the record needs more than the milligram.

    A daily dose total is the easiest number on a pain chart to extract, which is why quality measures count it. It is also among the weakest predictors that chart holds.

    A morphine milligram equivalent total is the easiest risk variable to pull from a pharmacy claim, which is why it anchors health-plan quality measures and point-of-sale edits. It is also a conversion with wide error bars, applied to patients whose metabolism changes what a milligram does. The chapter video A Dose Is Not a Diagnosis presents Chapter 17 of The Pained Brain by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Dr. KrisJay Fucanan, MD; the study-level evidence, with each paper’s limits, is in the Chapter 17 book companion. For the ordering physician, the practical question is what belongs in the record next to the dose.

    Where did the 90 MME threshold come from?

    The 2016 federal guideline told prescribers that any increase to 90 MME or beyond should be avoided or carefully justified, and it described its recommendations as voluntary. A quality-measurement body then specified high-dosage use as an average of 90 MME or more for at least 15 days, instructed that "a lower rate indicates better performance," and had moved its line down from 120 to 90 in 2019 for alignment. Medicare directed drug plans to install a care-coordination edit at 90. The agency’s 2024 guidance says those edits "should not be implemented as a prescribing limit or as a substitute for clinical judgment," while a 2026 memorandum reports high-dosage use monthly to plan sponsors, with several such measures displayed as Part D Star Rating measures. That is the structural driver: a plan’s public rating moves with the milligram total, and the incentive flows down to the practice. The practice position concedes that prescribing ran too high and that the milligram is a real hazard. The objection is to treating a conversion as a diagnosis.

    How accurate is a morphine milligram equivalent conversion?

    Conversion variance is large enough to move a patient across the line. Asked to convert identical doses, 319 clinicians produced a mean of 176 milligrams for a 75-microgram fentanyl patch, with a standard deviation of 117, and 193 milligrams for 40 milligrams of methadone, with a standard deviation of 201. The most recent systematic evaluation of conversion factors found 24 studies supporting factors across 29 mapped opioids and called for continued validation. The 2022 guideline took the specific number out of its recommendation statement, stated that no dosage threshold eliminates risk, and directed that buprenorphine not be counted in the daily total because of its ceiling effect on respiratory depression. A metric that cannot represent a partial agonist, and cannot be reproduced by two pharmacists reading one chart, is a screening flag. It is not a risk assessment.

    What predicts opioid overdose better than dose?

    The cleanest head-to-head comparison used 560,057 fee-for-service Medicare beneficiaries without cancer. The federal dose-based measures captured 29.29 percent of overdose episodes over twelve months; machine-learning models captured 90.57 percent. Total dose ranked among the top ten predictors, next to substance use disorder diagnoses, age, disability status and benzodiazepine fills, out of 268 candidates. The limit is real: positive predictive value ran 0.18 to 0.22 percent because overdose is rare. A simpler five-variable model validated at a c-statistic of 0.75.

    Single variables carry larger effects than dose bands. In opioid-naive adults starting a first prescription, comorbid substance use disorder carried an adjusted hazard ratio of 2.74, and age 75 or older 3.22. Concurrent benzodiazepines carried a hazard of 5.05 in the first 90 days of overlap, falling to 1.87 on days 91 to 180, so a new co-prescription is a different exposure from a long-stable one. At the population level, high-dose prescribing alone accounted for an attributable fraction of 0.07 of fatal overdoses, while critical encounters such as a nonfatal overdose or release from incarceration accounted for 0.37.

    Terrain variables a dose total cannot hold

    The milligram enters a person whose physiology changes its effect. CYP2D6 poor metabolizers form 96 percent less morphine from codeine; ultrarapid metabolizers form 45 percent more. After hip and knee arthroplasty, the direction of an opioid receptor variant’s effect on morphine dose reversed with diabetes status, even though diabetes, genotype and their interaction explained only 2.7 percent of dosing variance. A perioperative review describes excess adiposity altering distribution, hepatic clearance and renal elimination, and notes that sleep apnea is common in the same population. Those are two biological drivers, hepatic enzyme capacity and an insulin-resistant, adipose terrain, sitting under the structural one above.

    Measura [Cardiometabolic and Autonomic Health Analysis] does not offer pharmacogenetic genotyping or sleep studies; both are different tests done elsewhere. What it adds is the terrain that the chart otherwise infers:

    When a dose change is already under discussion

    None of this is a dosing recommendation, and the evidence on changes cuts both ways. What it shows consistently is that the manner matters. Monthly reductions above 30 percent carried an adjusted overdose hazard of 5.33 the following month, while reductions of 10 percent or less carried none. In a trial emulation of stable patients, eleven-month overdose or suicide risk was 0.96 percent with no change, 1.10 percent with tapering and 1.28 percent with abrupt discontinuation. After tapering, adherence to antihypertensive and diabetes medications fell to 0.60 and 0.69 of baseline, a measurable reason to hold a metabolic baseline before any plan changes. In high-risk veterans, a mandated interdisciplinary case review in place of a cut reduced discontinuation by 11.16 percentage points and all-cause mortality by 3.31. Measurement belongs in that review.

    Documentation, standing orders and quality reporting

    A high-dosage measure counts milligrams; nothing in it records whether anyone looked for the generator or the terrain. The chart can. A standing order can attach metabolic labs and body composition to patients on long-term therapy for chronic non-cancer pain, and cognitive and balance testing to those 75 and older, so the decision is reproducible across clinicians. Findings entered as structured fields in the chart sit next to the dose when a plan review or a pharmacy edit arrives. The same findings support the cardiometabolic documentation that MIPS and quality reporting already expects. Locating the generator is its own workup, covered in documentation before the diagnostic nerve block, and what the easiest first treatment takes from a patient over years is taken up in quality-adjusted life years in spine care.

    Frequently asked questions

    Does the high-dosage quality measure require clinicians to reduce stable doses?

    No. The measure is a health-plan rate, not a clinical directive. Federal clinician guidance warns against misinterpreting cautionary dosage thresholds as mandates for dose reduction, and Medicare guidance states that its edits are not a prescribing limit. The 2016 guideline offered established patients above 90 MME the opportunity to reevaluate, not a cut. How quality measures intersect with documentation is summarized under HEDIS and value-based care.

    Which chart variables add most to dose in overdose risk?

    Substance use disorder, age 75 or older, concurrent benzodiazepines in the first 90 days, and recent critical encounters such as a nonfatal overdose each carried effects larger than dose bands in the cited cohorts. Multivariable models outperformed dose-only rules, though low prevalence keeps positive predictive value small. Practice-level criteria for who receives additional measurement are in selection criteria.

    Should buprenorphine be included in a daily MME total?

    The 2022 guideline says it should not, citing a ceiling effect on respiratory depression, and notes that the dose-response studies behind the thresholds examined full agonists only. Medicare guidance also excludes buprenorphine for opioid use disorder from its safety edits. A total that includes it overstates exposure. The broader case for measuring the patient rather than the number is in the clinical rationale.

    Does Measura offer pharmacogenetic testing?

    No. CYP2D6 and opioid receptor genotyping are genetic tests performed elsewhere, and the implementation guideline itself cautions that genotype does not settle phenotype. Measura measures metabolic, body composition, vascular, autonomic, nerve and cognitive function and reports to the ordering physician. How different specialties use those measurements is described in specialty applications.

    Where does this measurement fit in an existing visit structure?

    Cognitive status and fall risk are already part of wellness documentation for older patients, which makes that visit a sensible place to add metabolic and body composition baselines for someone on long-term therapy for chronic pain. Captured there, the baseline exists before any review of the dose rather than after it. Workflow details are in annual wellness visit integration.

    What does 90 MME mean?

    It is a daily total of 90 morphine milligram equivalents, the level the 2016 federal guideline told prescribers to avoid or carefully justify. A quality-measurement body then defined high-dosage use as an average of 90 MME or more for at least 15 days, lowered from 120 in 2019, and Medicare directed drug plans to place a care-coordination edit at 90. The 2022 guideline removed the specific number and stated that no threshold eliminates risk.

    What are morphine milligram equivalents (MME)?

    A conversion that restates each opioid dose as an equivalent amount of morphine, so a daily total can be compared across drugs. It is the easiest risk variable to pull from a pharmacy claim, which is why it anchors health-plan quality measures and point-of-sale edits. Its error bars are wide: 319 clinicians converting a 75-microgram fentanyl patch produced a mean of 176 milligrams with a standard deviation of 117.

    Document the patient, not only the dose

    See how the Measura protocol adds metabolic, body composition and cognitive baselines to the record for patients with chronic pain, with results returned to the ordering physician.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • National Committee for Quality Assurance (2026). Use of Opioids at High Dosage (HDO) – HEDIS measure page. NCQA HEDIS Measure Library. https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/use-of-opioids-at-high-dosage-hdo/
    • Centers for Medicare & Medicaid Services (2024). Frequently Asked Questions about Formulary-Level Opioid Point-of-Sale Safety Edits (July 5, 2024). CMS.gov (guidance document). https://www.cms.gov/files/document/frequently-asked-questions-about-formulary-level-opioid-point-sale-safety-edits-july-5-2024.pdf
    • Dowell, D., Ragan, K. R., Jones, C. M., Baldwin, G. T., & Chou, R. (2022). CDC Clinical Practice Guideline for Prescribing Opioids for Pain – United States, 2022. MMWR. Recommendations and Reports, 71(3), 1–95. https://doi.org/10.15585/mmwr.rr7103a1
    • Rennick, A., Atkinson, T., Cimino, N. M., Strassels, S. A., McPherson, M. L., & Fudin, J. (2016). Variability in Opioid Equivalence Calculations. Pain Medicine, 17(5), 892–898. https://doi.org/10.1111/pme.12920
    • Lo-Ciganic, W.-H., Huang, J. L., Zhang, H. H., Weiss, J. C., Wu, Y., Kwoh, C. K., Donohue, J. M., Cochran, G., Gordon, A. J., Malone, D. C., Kuza, C. C., & Gellad, W. F. (2019). Evaluation of Machine-Learning Algorithms for Predicting Opioid Overdose Risk Among Medicare Beneficiaries With Opioid Prescriptions. JAMA Network Open, 2(3), e190968. https://doi.org/10.1001/jamanetworkopen.2019.0968
    • Larochelle, M. R., Bernstein, R., Bernson, D., Land, T., Stopka, T. J., Rose, A. J., Bharel, M., Liebschutz, J. M., & Walley, A. Y. (2019). Touchpoints – Opportunities to predict and prevent opioid overdose: A cohort study. Drug and Alcohol Dependence, 204, 107537. https://doi.org/10.1016/j.drugalcdep.2019.06.039
    • Hernandez, I., He, M., Brooks, M. M., & Zhang, Y. (2018). Exposure-Response Association Between Concurrent Opioid and Benzodiazepine Use and Risk of Opioid-Related Overdose in Medicare Part D Beneficiaries. JAMA Network Open, 1(2), e180919. https://doi.org/10.1001/jamanetworkopen.2018.0919
    • Jurewicz, A., Gasiorowska, A., Leźnicka, K., Maciejewska-Skrendo, A., Pawlak, M., Machoy-Mokrzyńska, A., Bohatyrewicz, A., & Tarnowski, M. (2025). Do Diabetes and Genetic Polymorphisms in the OPRM1 and COMT Genes Modulate the Postoperative Opioid Demand and Pain Perception in Osteoarthritis Patients After Total Knee and Hip Arthroplasty? Journal of Clinical Medicine, 14(13), 4634. https://doi.org/10.3390/jcm14134634
    • Glanz, J. M., Xu, S., Narwaney, K. J., McClure, D. L., Rinehart, D. J., Ford, M. A., Nguyen, A. P., & Binswanger, I. A. (2023). Association Between Opioid Dose Reduction Rates and Overdose Among Patients Prescribed Long-Term Opioid Therapy. Substance Abuse, 44(3), 209–219. https://doi.org/10.1177/08897077231186216
    • Li, Y., Barr, K. D., Trafton, J. A., Oliva, E. M., Garrido, M. M., Frakt, A. B., & Strombotne, K. L. (2023). Impact of Mandated Case Review Policy on Opioid Discontinuation and Mortality Among High-Risk Long-Term Opioid Therapy Patients: The STORM Stepped-Wedge Cluster Randomized Controlled Trial. Subst Abus, 44(4), 292–300. https://doi.org/10.1177/08897077231198299

    Related reading

  • Dr. Gurpreet Singh Padda presenting the title card Does She Hurt? Pain in the Elderly, The Pained Brain, Chapter 16

    Delirium in Elderly Patients: Rule Out Pain Before Sedation

    Does She Hurt? Pain in the Elderly | The Pained Brain, Chapter 16

    Delirium in Elderly Patients: Rule Out Pain Before Sedation

    In elderly patients with dementia, untreated pain is a measurable driver of delirium: across 30 studies of older inpatients, severe pain carried 3.42 times the odds. Pain belongs on the workup before any sedative is ordered.

    Acute confusion and agitation in an older patient with dementia are usually treated as behavior. The evidence places untreated pain among the drivers, and the workup that separates the two can be built into routine geriatric screening.

    Delirium in elderly patients with dementia is usually charted as a behavioral event and managed as one, although a measurable share of it tracks pain that nobody assessed. The distinction changes the order: an analgesic workup before a sedative, and baselines that let a change in cognition or balance be recognized as a change. The chapter video, Does She Hurt? Pain in the Elderly, presents chapter 16 of The Pained Brain by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Dr. KrisJay Fucanan, MD. Each study, with what it can and cannot show, is summarized in the book companion for chapter 16.

    Is pain a risk factor for delirium in elderly patients?

    Among 541 hip-fracture patients without delirium at enrollment, 16 percent became delirious. In cognitively intact patients, severe pain carried a relative risk of 9.0, and receiving under 10 milligrams of parenteral morphine equivalents a day carried 5.4; too much pain and too little analgesia behaved as the same exposure. Pooled across 30 studies of older inpatients, pain at rest carried an odds ratio of 2.14 for delirium and severe pain 3.42, while pain on movement did not reach significance. Before elective orthopedic surgery, in 200 patients with a median age of 69, preoperative chronic pain independently predicted postoperative delirium at an adjusted odds ratio of 2.488.

    The inpatient picture in established neurocognitive disorder is starker. In 292 hospitalized patients with a mean age of 87.8, observational pain behaviors were present in 62.4 percent, and only 20.3 percent of those were receiving an analgesic at admission. Three-month mortality carried an adjusted hazard of 2.39. That is a single-center observational association, not a causal estimate, but it describes a group in which pain is common, untreated and prognostically meaningful.

    Why is pain under-recorded where agitation orders are written?

    Only 24.4 percent of nursing-home admissions with severe cognitive impairment were assessed by staff observation rather than a self-report instrument they could not use. When the two approaches were compared in separate samples, self-report recorded moderate to severe pain in 9.60 percent and staff observation in 34.04 percent. The chart therefore under-records pain precisely where agitation orders are written.

    The trial evidence is directional and honest in both directions. In 352 residents with dementia and agitation across 60 Norwegian units, a stepwise analgesic protocol reduced agitation by 17 percent, a treatment effect of −7.0, and the effect faded to −3.2 by week 12 after withdrawal. Anxiety and irritability items did not change significantly. Scheduled acetaminophen given to 95 residents selected for low quality of life rather than pain or agitation did nothing. Selection is the variable: treat identified pain, not everyone.

    Meanwhile the sedative has a number attached. In veterans with dementia, the number needed to harm for one excess death within 180 days was 26 for haloperidol and 50 for quetiapine.

    What drives missed pain and sedative harm in older patients?

    The first biological driver is nociception itself, which in dementia surfaces as resistance to care, calling out and nighttime restlessness rather than a verbal report. The second is pharmacokinetic: hepatic clearance of most drugs falls 10 to 40 percent with age and the aging brain is more sensitive at a given level, so each sedating agent adds more than its dose suggests. Emergency visits for medication harm ran 12.1 per 1,000 adults over 65 against 5.0 in younger adults. The structural driver is measurement design. When a quality metric tracked antipsychotics alone, prescribing shifted toward other psychotropics. And in the one emergency department trial of a dementia pain scale, 602 older adults with suspected fractures waited a median of 83 minutes for analgesia against 82. A scale without an attached order changes the chart, not the patient.

    Dr. Padda’s own position is the one he reaches after decades of practice: the medication list of an older patient is itself a diagnosis to be read, and the answer to a behavior is a search for its generator.

    Where Measura fits: baselines that make change visible

    Measura [Cardiometabolic and Autonomic Health Analysis] is a testing service. It performs no procedures and no treatment, does not diagnose delirium or measure pain, and returns results to the ordering physician. Its role is the reference record that makes a later change interpretable.

    • Cognition. A cognitive assessment documents memory and executive function at baseline, so an acute decline can be distinguished from the trajectory. It is not a pain instrument, and a score does not stand in for observational pain assessment.
    • Orthostatic physiology. Continuously measured initial orthostatic hypotension appeared in 29.0 percent of adults 65 and over against 5.6 percent with intermittent readings. Cardiac autonomic reflex tests document heart rate and blood pressure responses to position change and breathing.
    • Balance. Pain in two or more sites raised fall rates 1.53-fold in adults 70 and older; vestibular and balance testing documents the fall-risk side of that equation.
    • Muscle and metabolism. Sarcopenia and chronic pain co-occur at an odds ratio of 1.52, and in patients 65 and over grip strength predicted epidural response at 1.142 per kilogram, with thresholds of 26.5 kg in men and 16.5 kg in women. Bioimpedance body composition and laboratory panels document lean mass and the glycemic picture; 29.2 percent of Americans over 65 have diabetes and 48.8 percent prediabetes.

    Standing orders, the annual wellness visit and documentation

    The annual wellness visit already asks for cognitive status and fall risk, which is where a cognitive baseline, a standing blood pressure and balance findings belong, recorded before the admission that makes them urgent. The cognitive assessment and fall prevention pairing keeps both in one encounter. A standing order can specify that new agitation or acute confusion in a patient with dementia triggers an observational pain assessment and a medication review before any sedating agent is added, which converts the scale into an action. Documentation supports HEDIS and value-based care reporting as a record of care delivered, not as the reason for it.

    What the evidence does not settle

    Much of this is observational, and the trials that would settle it have not enrolled patients in their late eighties. Deprescribing alone did not reduce falls in community trials at high certainty, and dose changes cut both ways: in older adults on long-term opioid therapy, rapid tapering lowered overdose but raised all-cause mortality 1.28-fold. Removing a drug is a decision about a list; treating the patient requires finding the generator. Family-facing guidance on the standing reading is in what a seated blood pressure misses, and the earlier argument on injections is metabolic screening before repeat joint injections.

    Frequently asked questions

    How strongly does pain predict delirium in older inpatients?

    Pooled across 30 studies, pain at rest roughly doubled the odds of delirium and severe pain more than tripled them, while pain on movement was not significant. After hip fracture, severe pain in cognitively intact patients carried a relative risk of 9.0, with a wide interval. The inputs are observational and heterogeneous. The clinical rationale for measuring before acting applies directly.

    Should new agitation in dementia prompt a pain workup before an antipsychotic?

    The cluster-randomized Norwegian trial supports it: a stepwise analgesic protocol reduced agitation by 17 percent, and the effect faded when analgesia was withdrawn. Blanket scheduled acetaminophen in residents not selected for pain did nothing, so the workup should identify pain rather than assume it. Sedating agents carry measurable mortality. Specialty applications describes use in geriatric practice.

    Can a cognitive assessment detect pain or delirium?

    No. A cognitive assessment documents memory and executive function; it does not measure pain and does not diagnose delirium. Its value here is as a baseline, so an acute change can be recognized against a documented trajectory rather than attributed to progression. Pain in nonverbal patients still requires an observational tool. Cognitive assessment outlines what the test covers.

    Why document orthostatic physiology in patients with dementia who fall?

    Continuous measurement found initial orthostatic hypotension in 29.0 percent of adults 65 and over, against 5.6 percent with intermittent readings, and antihypertensive intensity was associated with serious fall injury in older adults. Pooled trials did not show excess falls with treatment, so the finding informs a prescriber review rather than withdrawal. Cardiac autonomic reflex tests describes the measurement.

    Which older patients belong on this standing order?

    Patients with dementia or cognitive impairment who develop new agitation, acute confusion, falls or declining mobility, and those carrying several sedating or pressure-lowering medications, are the practical core. Hip fracture and vertebral fracture histories raise the priority. The order should link assessment to an action. Practice-level selection criteria summarize who to test.

    Why is pain missed in older patients with dementia?

    Pain in dementia tends to show up as resistance to care, calling out and nighttime restlessness rather than a spoken complaint. Charts rely on self-report, which these patients cannot give. Only 24.4 percent of nursing-home admissions with severe cognitive impairment were assessed by staff observation, and observation recorded moderate to severe pain far more often than self-report did, 34.04 percent against 9.60 percent.

    What are the risks of antipsychotics for agitation in dementia?

    In veterans with dementia, the number needed to harm for one excess death within 180 days was 26 for haloperidol and 50 for quetiapine. Older patients also clear most drugs 10 to 40 percent more slowly, and the aging brain is more sensitive at a given level, so each sedating agent adds more than its dose suggests. That is why the pain workup comes first.

    Build baselines into geriatric screening

    See how the Measura protocol adds cognitive, autonomic, balance and body composition baselines to geriatric workflows, with results returned to the ordering physician.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Morrison, R. S., Magaziner, J., Gilbert, M., Koval, K. J., McLaughlin, M. A., Orosz, G., Strauss, E., & Siu, A. L. (2003). Relationship between pain and opioid analgesics on the development of delirium following hip fracture. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 58(1), 76-81. https://doi.org/10.1093/gerona/58.1.m76
    • White, N., Bazo-Alvarez, J. C., Koopmans, M., West, E., & Sampson, E. L. (2024). Understanding the association between pain and delirium in older hospital inpatients: systematic review and meta-analysis. Age and Ageing, 53(4), afae073. https://doi.org/10.1093/ageing/afae073
    • Mancinetti, F., Travaglini, E. G., Speziali, L., Gaspari, M., Ercolani, S., Mecocci, P., & Boccardi, V. (2026). Pain as an underrecognized geriatric syndrome in hospitalized older adults with major neurocognitive disorder: clinical correlates and outcomes. European Geriatric Medicine, 17(3), 1479-1488. https://doi.org/10.1007/s41999-026-01450-w
    • Dube, C. E., Morrison, R. A., Mack, D. S., Jesdale, B. M., Nunes, A. P., Liu, S.-H., & Lapane, K. L. (2020). Prevalence of Pain on Admission by Level of Cognitive Impairment in Nursing Homes. Journal of Pain Research, 13, 2663-2672. https://doi.org/10.2147/JPR.S270689
    • Shippee, T. P., Qin, X., Vick, R., Shippee, N. D., Parikh, R. R., Parsons, H. M., & Virnig, B. (2025). Underreporting of Pain for Short-Stay Nursing Home Residents in the Minimum Data Set 3.0?: Staff-Report, Self-Report, and the Role of Cognitive Impairment and Racial/Ethnic Identity. Journal of the American Medical Directors Association, 27(1), 105970. https://doi.org/10.1016/j.jamda.2025.105970
    • Husebo, B. S., Ballard, C., Sandvik, R., Nilsen, O. B., & Aarsland, D. (2011). Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ, 343, d4065. https://doi.org/10.1136/bmj.d4065
    • van Dam, P. H., Achterberg, W. P., Husebo, B. S., & Caljouw, M. A. A. (2020). Does paracetamol improve quality of life, discomfort, pain and neuropsychiatric symptoms in persons with advanced dementia living in long-term care facilities? A randomised double-blind placebo-controlled crossover (Q-PID) trial. BMC Medicine, 18(1), 407. https://doi.org/10.1186/s12916-020-01858-6
    • Lee, S., Lo, A. X., Hogan, T. M., van Oppen, J. D., Gettel, C. J., Lapointe-Shaw, L., Seidenfeld, J., Hirata, K., Aliberti, M. J. R., Healy, H. S., & Liu, S. W. (2026). A Systematic Review Evaluating Pain Assessment Strategies for Patients With Dementia in the Emergency Department: The Geriatric ED Guidelines 2.0. Academic Emergency Medicine, 33(2), e70230. https://doi.org/10.1111/acem.70230
    • Tran, J., Hillebrand, S. L., Meskers, C. G. M., Iseli, R. K., & Maier, A. B. (2021). Prevalence of initial orthostatic hypotension in older adults: a systematic review and meta-analysis. Age and Ageing, 50(5), 1520-1528. https://doi.org/10.1093/ageing/afab090
    • Kim, S. H., Park, S. J., Yoon, K. B., Jun, E.-K., Cho, J., & Kim, H. J. (2022). Influence of Handgrip Strength and Psoas Muscle Index on Analgesic Efficacy of Epidural Steroid Injection in Patients With Degenerative Lumbar Spinal Disease. Pain Physician, 25(7), E1105-E1113. https://pubmed.ncbi.nlm.nih.gov/36288597/

    Related reading

  • Dr. Gurpreet Singh Padda presenting the title card The Goal Was Never to Manage Your Pain Forever, The Pained Brain, Chapter 15

    Corticosteroid-Induced Hyperglycemia After Joint Injections

    The Goal Was Never to Manage Your Pain Forever | The Pained Brain, Chapter 15

    Corticosteroid-Induced Hyperglycemia After Joint Injections

    Corticosteroid-induced hyperglycemia after a joint injection is measurable: in patients with type 2 diabetes, one immediate-release triamcinolone knee injection produced a median maximum-glucose rise of 169.1 mg/dL over days 1 to 3, and 93 percent exceeded 250 mg/dL. A review of 7 studies found a rise in every study and advised monitoring for up to a week.

    Most injection referrals document the joint and leave out the patient’s metabolism. The evidence on systemic steroid effects and regenerative outcomes argues for measuring glucose control, body composition and fall risk before the next procedure is scheduled.

    Corticosteroid-induced hyperglycemia after a joint or epidural injection rarely appears in the referring chart, yet the literature now describes systemic effects that primary care owns: glycemic excursions, adrenal suppression and fracture. The same metabolic variables predict which patients fail a regenerative injection. The chapter video, The Goal Was Never to Manage Your Pain Forever, presents chapter 15 of The Pained Brain by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Dr. KrisJay Fucanan, MD. Trial-level detail, with the limits of each study, is in the book companion for chapter 15.

    What does a steroid injection do to blood sugar, adrenal function and bone?

    Three signals deserve a place in the referring chart. In patients with type 2 diabetes and an A1c of 6.5 to 9.0 percent, continuous glucose monitoring after one immediate-release triamcinolone knee injection showed a median maximum-glucose rise of 169.1 mg/dL over days 1 to 3; 93 percent exceeded 250 mg/dL, and time in range fell to 48 percent against 62 percent with the extended-release formulation. That was a post hoc analysis of thirty-three patients, but a systematic review of 7 studies and 72 patients found a rise in every study and advised monitoring for up to a week.

    A double-blind comparison of epidural triamcinolone found hypothalamic-pituitary-adrenal suppression lasting 19.7 days at 40 mg against 8.0 days at 20 mg, with no difference in analgesia. And among 25,062 Medicare patients given epidural steroid for radiculopathy, mean age 76 and 74 percent female, fractures at typical osteoporotic sites ran 49.1 per 1,000 person-years against 35.2 in unexposed patients, a hazard of 1.39 overall and 1.54 at the vertebrae, with higher early risk after three or more injections in a year.

    Why do the side effects of repeat steroid injections go untracked?

    Two biological drivers concentrate the risk. Insulin resistance determines how far glucose travels after a steroid load, and adiposity raises both the mechanical demand on the joint and the likelihood that the injection will be repeated. The third driver is structural. Each injection is documented as a discrete procedure, relief arrives quickly, and nobody owns the cumulative record across episodes. Of osteoarthritis patients in British primary care, 10.8 percent had a steroid injection, and 40 percent of that group had repeat injections. The rheumatology guideline that strongly recommends the injection sets no numeric cap on frequency, so the running total is tracked only if the referring physician tracks it.

    Dr. Padda has said plainly that he spent years reassuring patients whose A1c sat in the prediabetic band. That reassurance does not survive the regenerative outcome data, and it has no place in a referral note.

    Does diabetes make PRP less likely to work?

    Where platelet-rich plasma is under consideration, the metabolic workup becomes prognostic. In a retrospective case-control study of 120 patients with Achilles or patellar tendinopathy, 60 of them with diabetes or prediabetes, the odds of failing to reach the minimal important difference were 2.41, and 2.54 for a 20-point improvement. Glycated hemoglobin independently predicted a poor outcome at an odds ratio of 1.16, and body mass index at 1.02. In knee cohorts, body mass index and radiographic grade were the independent predictors of failure, which reached 15.3 percent at a mean of nearly five years.

    Growth-factor content in the preparation did not differ between lean and obese patients. Inflammatory content did track body mass: interleukin-18 rose with body mass index and predicted weaker functional gains in a small single-injection series. The preparation is not the main variable. The recipient is, and the recipient can be measured before the procedure is scheduled.

    Who should have blood sugar checked before a steroid injection?

    Metabolic health is the exception rather than the default in adults: under 12.2% of US adults qualified on NHANES 2009–2016, and under 7% on the tighter criteria applied after 2021. Reasonable candidates include:

    • Patients with known diabetes or an A1c in the prediabetic range, before any corticosteroid injection, so glucose monitoring for the following week can be planned in advance.
    • Patients with obesity, where body mass index conflates fat mass with lean mass.
    • Older adults receiving epidural steroid, particularly those approaching three or more injections in a year, where fracture exposure and fall risk belong in one plan.
    • Patients referred for a regenerative injection, where A1c and body composition inform the expected response.
    • Patients within three months of planned knee arthroplasty. Across 58,337 primary knee replacements, corticosteroid injection in that window carried an infection odds ratio of 1.21 on a 2.74 percent base rate, and hyaluronic acid 1.55, a timing signal the surgeon and the referring physician should share.

    What Measura measures, and what it does not

    Measura [Cardiometabolic and Autonomic Health Analysis] is a testing service. It performs no injections, no imaging and no treatment, and results return to the ordering physician. Three measurements apply to this pathway: laboratory panels for the glycemic and lipid picture; bioimpedance body composition for fat and lean compartments; and vestibular and balance testing for older patients whose fracture exposure after epidural steroid makes fall risk a management question. None of these measures bone density, and a balance result does not substitute for one. Pairing balance findings with a cognitive baseline follows the cognitive assessment and fall prevention workflow.

    Standing orders, the referral letter and documentation

    A standing order that attaches a laboratory panel including A1c and a body composition measurement to referrals for joint or epidural injection takes the decision out of the individual encounter, which is the only way the cumulative record gets built. Results filed as discrete data in the record remain visible when the procedure note returns. The referral letter can ask that the note record the agent, formulation and dose, since the glycemic and adrenal effects scale with them. One Medicare contractor policy already allows no more than four epidural steroid sessions in a spinal region over a rolling year and rejects a predetermined series as not medically reasonable. Cardiometabolic findings also support documentation that MIPS and quality reporting asks practices to capture, as documentation rather than a reason to test.

    What the evidence does not settle

    The cohort harm signals carry confounding by indication. When steroid was compared against hyaluronic acid, which ensured both arms had knees judged worth injecting, joint-space narrowing progressed at a rate ratio of 1.00. The fracture data are claims-based in a population that may be frailer at baseline, and the tendinopathy outcome data are retrospective. Exercise remains the comparator an injection has to beat: in a randomized trial of 273 patients, a year of exercise-based physical therapy outperformed a glucocorticoid injection by 22.70 WOMAC points. The practice position is that the injection is a bridge and the metabolic work is the destination, which makes measuring the terrain the referring physician’s share of the plan. The patient-facing version is what a cortisone shot does to blood sugar.

    Frequently asked questions

    Should patients with diabetes monitor glucose after a corticosteroid joint injection?

    The data support it. After one immediate-release triamcinolone knee injection, patients with type 2 diabetes had a median maximum-glucose rise of 169.1 mg/dL, and median time to 250 mg/dL was 6 hours. A review of 7 studies advised monitoring for up to a week. Any change to diabetes therapy remains the treating physician’s decision. Interpreting the report covers how Measura results reach the ordering physician.

    Does A1c predict response to platelet-rich plasma?

    In one retrospective study of 120 tendinopathy patients, each unit of glycated hemoglobin raised the odds of a poor outcome 1.16-fold, and diabetes or prediabetes more than doubled the odds of missing a meaningful improvement. Growth-factor content did not differ by body mass, which points to the recipient tissue rather than the preparation. Prospective confirmation is still lacking. The clinical rationale for measuring first follows the same logic.

    Is epidural steroid associated with fracture in older adults?

    In 25,062 Medicare patients with radiculopathy, epidural steroid was associated with osteoporotic-site fractures at 49.1 per 1,000 person-years against 35.2, with a vertebral hazard of 1.54. Claims data cannot exclude frailer patients being selected for injection, and a small low-dose cohort found no bone density change. Fall risk still belongs in the plan. Practice-level selection criteria summarize who to test.

    Where does metabolic testing fit in the annual wellness visit?

    That visit already records fall risk and cognitive status, which makes it the natural place to attach laboratory and body composition measurement for a patient with chronic joint or spine pain. Doing it there means the baseline exists before the first injection referral rather than being reconstructed after the third. Annual wellness visit integration describes the workflow.

    Does Measura perform or recommend injections?

    No. Measura measures metabolic, body composition, vascular, autonomic, nerve, balance and cognitive function and reports to the ordering physician. Injection decisions, dosing and timing stay with the treating clinicians. The testing supplies the context a procedure note lacks, and what changes for the patient describes how findings are used.

    How long does blood sugar stay high after a steroid injection?

    The rise starts within hours and can last most of a week. In patients with type 2 diabetes given one immediate-release triamcinolone knee injection, median time to reach 250 mg/dL was 6 hours, and the largest rise came over days 1 to 3. A review of 7 studies found a rise in every study and advised monitoring glucose for up to a week after the shot.

    Is a cortisone shot bad for people with diabetes?

    It pushes glucose well out of range for most of them. After one immediate-release triamcinolone knee injection, 93 percent of patients with type 2 diabetes exceeded 250 mg/dL, and time in range fell to 48 percent, against 62 percent with the extended-release formulation. That is a reason to plan a week of glucose monitoring before the injection, not after it. Any change to diabetes medicine stays with the treating physician.

    How many steroid injections can you get in a year?

    The rheumatology guideline that recommends joint injections sets no numeric cap, so the running total is tracked only if someone tracks it. One Medicare contractor policy allows no more than four epidural steroid sessions in a spinal region over a rolling year. In older Medicare patients, fracture risk ran higher early on after three or more epidural injections in a year.

    Attach measurement to the injection pathway

    See how the Measura protocol adds metabolic, body composition and balance testing to injection referrals, with results returned to the ordering physician.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Spitzer, A. I., Rodbard, H. W., Iqbal, S. U., Nakazawa, M., DiGiorgi, M., & Winston, R. (2024). Extended-Release Versus Immediate-Release Triamcinolone Acetonide in Patients Who Have Knee Osteoarthritis and Type 2 Diabetes Mellitus. The Journal of Arthroplasty, 39(9 Suppl 2), S218-S223.e1. https://doi.org/10.1016/j.arth.2024.05.055
    • Choudhry, M. N., Malik, R. A., & Charalambous, C. P. (2016). Blood Glucose Levels Following Intra-Articular Steroid Injections in Patients with Diabetes: A Systematic Review. JBJS Reviews, 4(3), e5. https://doi.org/10.2106/JBJS.RVW.O.00029
    • Sim, S. E., Hong, H. J., Roh, K., Seo, J., & Moon, H. S. (2020). Relationship Between Epidural Steroid Dose and Suppression of Hypothalamus-Pituitary-Adrenal Axis. Pain Physician, 23(4S), S283-S294. https://pubmed.ncbi.nlm.nih.gov/32942788/
    • Yun, H., Liu, Y., Curtis, J. R., Saag, K., D’Erasmo, G., Haseltine, K., & Stein, E. M. (2025). Epidural steroid injections and fracture incidence among older individuals with radiculopathy. Journal of Bone and Mineral Research, 40(2), 176–183. https://doi.org/10.1093/jbmr/zjae162
    • Whitehouse, M. R., Judge, A., Hawley, S., Prats Uribe, A., Delmestri, A., Matharu, G., Moore, A., Palmer, C., Wylde, V., Anderson, E., Donovan, R., Jameson, C., Snelling, N., Blom, A. W., Gooberman-Hill, R., Barker, K., & Prieto-Alhambra, D. (2025). RecUrrent Intra-articular Corticosteroid injections in Osteoarthritis: the RUbICOn mixed-methods study. Health Technology Assessment, 29(56), 1-167. https://doi.org/10.3310/LFAJ9337
    • Abate, M., Paganelli, R., Pellegrino, R., Di Iorio, A., & Salini, V. (2024). Platelet Rich Plasma Therapy in Achilles and Patellar Tendinopathies: Outcomes in Subjects with Diabetes (A Retrospective Case-Control Study). Journal of Clinical Medicine, 13(18), 5443 (article number from DOI; PubMed record lists volume 13, issue 18). https://doi.org/10.3390/jcm13185443
    • Alessio-Mazzola, M., Lovisolo, S., Sonzogni, B., Capello, A. G., Repetto, I., Formica, M., & Felli, L. (2021). Clinical outcome and risk factor predictive for failure of autologous PRP injections for low-to-moderate knee osteoarthritis. Journal of Orthopaedic Surgery (Hong Kong), 29(2), 23094990211021922. https://doi.org/10.1177/23094990211021922
    • Wiciński, M., Szwedowski, D., Wróbel, Ł., Jeka, S., & Zabrzyński, J. (2022). The Influence of Body Mass Index on Growth Factor Composition in the Platelet-Rich Plasma in Patients with Knee Osteoarthritis. International Journal of Environmental Research and Public Health, 20(1), 40 (article number from DOI; PubMed record lists volume 20, issue 1). https://doi.org/10.3390/ijerph20010040
    • Richardson, S. S., Schairer, W. W., Sculco, T. P., & Sculco, P. K. (2019). Comparison of Infection Risk with Corticosteroid or Hyaluronic Acid Injection Prior to Total Knee Arthroplasty. The Journal of Bone and Joint Surgery. American Volume, 101(2), 112-118. https://doi.org/10.2106/JBJS.18.00454
    • Lee, M., Jing, C., & Lee, K. (2025). Physical therapy vs. glucocorticoid injection in patients with meniscal tears and knee osteoarthritis: a multi-center, randomized, controlled trial. BMC Medicine, 23(1), 277. https://doi.org/10.1186/s12916-025-04113-y

    Related reading